FVIII
Synonyms
F8, Coagulation factor VIII, AHF, Coagulation Factor VIII, Procoagulant Component, Antihemophilic Factor, F8C, Coagulation Factor VIII A1 Domain, Coagulation Factor VIII C2 Domain, Coagulation Factor VIIIc, Factor VIII F8B, Factor VIIIF8B, Hemophilia A, DXS1253E, FVIII, HEMA, F8B, Factor VIII, Procoagulant component
Description
Coagulation factor VIII (F8), along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.
KO Status
F0
Drug Information
Launched drugs: 9
Drugs in clinical trials: 9
Latest Research Phase: Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Von Willebrand factor (LFB)
vWF-SD-35-DH
Approved
Lfb Biotechnologies
von Willebrand Diseases
NCT Number
NCT02488525
NCT01949220
Intervention Type
Drug
Indications
Heart Failure
Von Willebrand Disease
Study Phase
Phase 3
N/A
Recruitment Status
Terminated
Completed
Protein C activated (Kaketsuken/Teijin)
Approved
Kaketsuken, Teijin Pharma
Pulmonary Embolism, Purpura, Venous Thrombosis
Factor VIII/von Willebrand factor (Bio Products Laboratory)
Approved
Bio Products Laboratory Ltd
Hemophilia A
NCT Number
NCT01811875
NCT02246881
NCT02250482
NCT00404300
NCT02246868
NCT00387192
NCT02246894
Intervention Type
Biological
Biological
Biological
Drug
Biological
Drug
Biological
Indications
Haemophilia A
Von Willebrand Disease
Haemophilia A
Von Willebrand Disease
Haemophilia A
Von Willebrand Disease
Haemophilia A
Study Phase
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Recruitment Status
Terminated
Completed
Completed
Terminated
Completed
Terminated
Completed
Antihemophilic factor/von Willebrand factor complex (Human, Grifols Biologicals)
Approved
Grifols Sa
von Willebrand Diseases, Hemophilia A
NCT Number
NCT00555555
NCT00323856
NCT03095287
Intervention Type
Biological
Drug
Biological
Indications
Von Willebrand Disease
Severe Hemophilia A
Hemophilia A, Congenital
Study Phase
Phase 4
Phase 4
Phase 2
Recruitment Status
Active, not recruiting
Active, not recruiting
Terminated
Von Willebrand factor/coagulation factor VIII complex (human, Octapharma)
Approved
Octapharma
von Willebrand Diseases, Hemophilia A
NCT Number
NCT03204539
NCT04555785
NCT01365546
NCT03376516
NCT02954575
NCT04052698
NCT04053699
NCT04023019
NCT04106908
NCT01602419
NCT00557908
NCT03344003
Intervention Type
Drug
Other, Drug
Biological
Drug
Drug
Drug
Drug
Biological
Biological
Other
Drug
Drug
Indications
Hemophilia A With Inhibitor; Hemophilia A
Bleeding
Prevent Bleeding in Major Surgery
Severe Hemophilia A
Severe Hemophilia A
Von Willebrand Diseases
Von Willebrand Diseases
Hemophilia A
VWD - Von Willebrand's Disease
Von Willebrand Disease
Von Willebrand Disease
Hemophilia A
Study Phase
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Terminated
Not yet recruiting
Completed
Completed
Completed
Recruiting
Completed
Recruiting
Recruiting
Completed
Completed
Terminated
Human protein C (Baxalta)
Approved
Baxalta
Purpura Fulminans, Protein C Deficiency
NCT Number
NCT00157118
NCT00161720
NCT01127529
Intervention Type
Drug
Drug
Biological
Indications
Protein C Deficiency
Protein C Deficiency
Study Phase
Phase 2/Phase 3
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Antihemophilic factor/von Willebrand factor (CSL Behring)
Approved
Csl Behring Llc
von Willebrand Diseases, Hemophilia A
NCT Number
NCT02552576
NCT01213446
NCT01445197
NCT01224808
NCT01229007
NCT00941616
NCT00879541
NCT04657887
Intervention Type
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Indications
Von Willebrand Disease
Von Willebrand Disease
Hemophilia A
Von Willebrand Disease
Hemophilia A
Von Willebrand Disease
Hemophilia A
Von Willebrand Disease
Study Phase
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
N/A
Recruitment Status
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Recruiting
Von Willebrand factor (Recombinant)
BAX-111, rVWF, SHP-677
Approved
Baxalta
von Willebrand Diseases
NCT Number
NCT02283268
NCT02606045
NCT02973087
NCT04344860
NCT01410227
NCT02932618
NCT03879135
NCT00816660
Intervention Type
Biological
Drug
Biological
Drug
Biological, Drug
Biological
Biological
Biological
Indications
Von Willebrand Disease
Von Willebrand Diseases
Von Willebrand Disease
Von Willebrand Diseases; Postpartum Hemorrhage
Von Willebrand Disease
Von Willebrand Disease
Von Willebrand Disease
Von Willebrand Disease
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 1
Recruitment Status
Completed
Recruiting
Completed
Not yet recruiting
Completed
Recruiting
Recruiting
Completed
Valoctocogene roxaparvovec
BMN-270
NDA/BLA
Biomarin Pharmaceutical Inc
Hematologic Diseases, Blood Coagulation Disorders, Hemophilia A
NCT Number
NCT03370913
NCT03392974
NCT04323098
NCT03520712
NCT04684940
NCT02576795
Intervention Type
Biological
Biological
Biological
Biological
Biological
Biological
Indications
Hemophilia A
Hemophilia A
Hemophilia A
Hemophilia A; Gene Therapy; Clotting Disorders; Blood Disorder
Hemophilia A With Inhibitor; Hemophilia A With Anti Factor VIII
Severe Haemophilia A
Study Phase
Phase 3
Phase 3
Phase 3
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
Active, not recruiting
Recruiting
Enrolling by invitation
Recruiting
Active, not recruiting
Giroctocogene fitelparvovec
Phase 3 Clinical
Sangamo Therapeutics
Hemophilia A
NCT Number
NCT04370054
NCT03061201
Intervention Type
Biological
Biological
Indications
Hemophilia A
Hemophilia A
Study Phase
Phase 3
Phase 2
Recruitment Status
Recruiting
Active, not recruiting
SPK-8011
SPK-8011
Phase 3 Clinical
Spark Therapeutics Inc
Hemophilia A
NCT Number
NCT03003533
Intervention Type
Genetic
Indications
Hemophilia A
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
SPK-8016
SPK-8016
Phase 2 Clinical
Spark Therapeutics Inc
Hemophilia A
NCT Number
NCT03734588
Intervention Type
Genetic
Indications
Adeno-Associated Virus (AAV); Blood Coagulation Disorder; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Factor VIII (FVIII); Factor VIII (FVIII) Deficiency; Factor VIII (FVIII) Gene; Factor VIII (FVIII) Protein; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Gene Therapy; Gene Transfer; Hematologic Diseases; Hemorrhagic Disorders; Recombinant; Vector; Inhibitors
Study Phase
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
3K3A-APC
3K3A-APC
Phase 2 Clinical
University Of Southern California, The Scripps Research Institute, Socratech
Stroke
NCT Number
NCT02222714
NCT01660230
Intervention Type
Biological, Drug
Biological, Drug
Indications
Ischemic Stroke
Healthy
Study Phase
Phase 2
Phase 1
Recruitment Status
Completed
Completed
DTX-201
DTX-201, BAY-2599023
Phase 2 Clinical
Dimension Therapeutics
Hemophilia A
NCT Number
NCT03588299
Intervention Type
Drug
Indications
Hemophilia A
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
SHP-654
SHP-654, BAX-888
Phase 2 Clinical
Shire Pharmaceuticals, Baxalta
Hemophilia A
NCT Number
NCT03370172
Intervention Type
Drug
Indications
Hemophilia A
Study Phase
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
Human von Willebrand factor (Shandong Taibang Biological Products)
Phase 1 Clinical
Shandong Taibang Biological Products Co,Ltd
von Willebrand Diseases
AAV2-8-HLP-FVIII-V3 (University College London)
Phase 1 Clinical
University College London
Hemophilia A
Factor VIII gene therapy (Novartis)
Pending
Novartis Pharma Ag
Hemophilia A
Factor VIII gene therapy (Corautus Genetics)
Discontinued
Baxter International Inc, Via Pharmaceuticals
Hemophilia A
Factor VIII gene therapy (Chiron)
Discontinued
Novartis Pharma Ag, Inex Pharmaceuticals
Hemophilia A
TB-402
TB-402
Discontinued
University Of Leuven
Venous Thromboembolism
NCT Number
NCT01344954
NCT00793234
NCT00612417
NCT00618579
NCT00612196
Intervention Type
Drug
Drug
Drug
Drug
Drug
Indications
Prophylaxis of Venous Thromboembolic Events
Total Knee Replacement Surgery
Healthy
Healthy
Healthy
Study Phase
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Human fibrinogen/Human thrombin (Mallinckrodt)
PRO-0601
Withdrawn
Mallinckrodt
Postoperative Hemorrhage, Hemorrhage, Blood Loss, Surgical
NCT Number
NCT01527357
NCT01256190
Intervention Type
Biological
Biological, Device
Indications
Mild or Moderate Surgical Bleeding
Postoperative Hemorrhage
Study Phase
Phase 3
Phase 2
Recruitment Status
Completed
Completed
Drotrecogin alfa
LTC-203, LY-203638
Withdrawn
Eli Lilly And Company
Multiple Organ Failure, Hypotension, Sepsis
NCT Number
NCT00049777
NCT00067730
NCT00279214
NCT02885168
NCT00045760
NCT00568893
NCT00049764
NCT00604214
NCT00190788
NCT00568737
NCT00191724
NCT00112164
NCT00386425
NCT02843685
Intervention Type
Drug
Drug
Drug
Biological, Drug, Device
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Sepsis
Sepsis; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Infection
Sepsis; Septic Shock
Septic Shock
Sepsis
Severe Sepsis
Sepsis
Sepsis
Sepsis; Hypotension
Sepsis
Submassive Pulmonary Embolism
Respiratory Distress Syndrome, Adult
Severe Sepsis
Sepsis
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
References
Title
Authors
Source
Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data
Ivaskevicius V., Jurgutis R., Rost S., Muller A., Schmitt C., Wulff K., Herrmann F.H., Muller C.R., Schwaab R., Oldenburg J.,
Br. J. Haematol. 112:1062-1070(2001)
Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A
Theophilus B.D.M., Enayat M.S., Williams M.D., Hill F.G.H.,
Haemophilia 7:381-391(2001)
Mild haemophilia A discovered in a previously multi-operated 73-year-old man: characterization of a new mutation
Bauduer F., Ducout L., Bendriss P., Falaises B., Lavergne J.-M.,
Haemophilia 7:419-421(2001)
Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations
Timur A.A., Guergey A., Aktuglu G., Kavakli K., Canatan D., Olek K., Caglayan S.H.,
Haemophilia 7:475-481(2001)
Seven novel and four recurrent point mutations in the factor VIII (F8C) gene
Bogdanova N., Lemcke B., Markoff A., Pollmann H., Dworniczak B., Eigel A., Horst J.,
Hum. Mutat. 18:546-546(2001)
Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations
Vidal F., Farssac E., Altisent C., Puig L., Gallardo D.,
Thromb. Haemost. 85:580-583(2001)
Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A
Valleix S., Vinciguerra C., Lavergne J.-M., Leuer M., Delpech M., Negrier C.,
Blood 100:3034-3036(2002)
Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A
Mazurier C., Parquet-Gernez A., Gaucher C., Lavergne J.-M., Goudemand J.,
Br. J. Haematol. 119:390-392(2002)
Three novel point mutations causing haemophilia A
Sukarova-Stefanovska E., Zisovski N., Muratovska O., Kostova S., Efremov G.D.,
Haemophilia 8:715-718(2002)
The identification and classification of 41 novel mutations in the factor VIII gene (F8C)
Cutler J.A., Mitchell M.J., Smith M.P., Savidge G.F.,
Hum. Mutat. 19:274-278(2002)
Identification of seven novel mutations of F8C by DHPLC
Frusconi S., Passerini I., Girolami F., Masieri M., Linari S., Longo G., Morfini M., Torricelli F.,
Hum. Mutat. 20:231-232(2002)
A domain mutations in 65 haemophilia A families and molecular modelling of dysfunctional factor VIII proteins
Liu M., Murphy M.E.P., Thompson A.R.,
Br. J. Haematol. 103:1051-1060(1998)
Protein truncation test: detection of severe haemophilia a mutation and analysis of factor VIII transcripts
Maugard C., Tuffery S., Aguilar-Martinez P., Schved J.-F., Gris J.-C., Demaille J., Claustres M.,
Hum. Mutat. 11:18-22(1998)
Independent occurrence of the novel Arg2163 to His mutation in the factor VIII gene in three unrelated families with haemophilia A with different phenotypes
Theophilus B.D.M., Enayat M.S., Higuchi M., Kazazian H.H. Jr., Antonarakis S.E., Hill F.G.H.,
Hum. Mutat. 11:334-334(1998)
Fluorescent chemical cleavage of mismatches for efficient screening of the factor VIII gene
Freson K., Peerlinck K., Aguirre T., Arnout J., Vermylen J., Cassiman J.-J., Matthijs G.,
Hum. Mutat. 11:470-479(1998)
Identification of four novel mutations in the factor VIII gene: three missense mutations (E1875G, G2088S, I2185T) and a 2-bp deletion (1780delTC)
Tavassoli K., Eigel A., Dworniczak B., Valtseva E., Horst J.,
Hum. Mutat. Suppl. 1:S260-S262(1998)
Molecular diagnostics of 15 hemophilia A patients: characterization of eight novel mutations in the factor VIII gene, two of which result in exon skipping
Tavassoli K., Eigel A., Wilke K., Pollmann H., Horst J.,
Hum. Mutat. 12:301-303(1998)
Use of denaturing gradient gel blots to screen for point mutations in the factor VIII gene
Laprise S.L., Mak E.K., Killoran K.A., Layman L.C., Gray M.R.,
Hum. Mutat. 12:393-402(1998)
Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis
Williams I.J., Abuzenadah A., Winship P.R., Preston F.E., Dolan G., Wright J., Peake I.R., Goodeve A.C.,
Thromb. Haemost. 79:723-726(1998)
Factor VIII inhibitors in mild and moderate-severity haemophilia A
UK haemophilia centre directors organisation, Hay C.R.M., Ludlam C.A., Colvin B.T., Hill F.G.H., Preston F.E., Wasseem N., Bagnall R., Peake I.R., Berntorp E., Mauser Bunschoten E.P., Fijnvandraat K., Kasper C.K., White G., Santagostino E.,
Thromb. Haemost. 79:762-766(1998)
Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954-->Leu substitution in the factor VIII A3 domain
Keeling D.M., Sukhu K., Kemball-Cook G., Waseem N., Bagnall R., Lloyd J.V.,
Br. J. Haematol. 105:1123-1126(1999)
Screen of 55 Slovenian haemophilia A patients: identification of 2 novel mutations (S-1R and IVS23+1G-->A) and discussion of mutation spectrum
Strmecki L., Benedik-Dolnicar M., Vouk K., Komel R.,
Hum. Mutat. 13:413-413(1999)
Mutational-screening in the factor VIII gene resulting in the identification of three novel mutations, one of which is a donor splice mutation
Moeller-Morlang K., Tavassoli K., Eigel A., Pollmann H., Horst J.,
Hum. Mutat. 13:504-504(1999)
Start of UK confidential haemophilia A database: analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch
The haemophilia centres, Waseem N.H., Bagnall R., Green P.M., Giannelli F.,
Thromb. Haemost. 81:900-905(1999)
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor
Jacquemin M., Lavend'homme R., Benhida A., Vanzieleghem B., d'Oiron R., Lavergne J.-M., Brackmann H.H., Schwaab R., VandenDriessche T., Chuah M.K.L., Hoylaerts M., Gilles J.G.G., Peerlinck K., Vermylen J., Saint-Remy J.-M.R.,
Blood 96:958-965(2000)
Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure
Liu M.-L., Shen B.W., Nakaya S., Pratt K.P., Fujikawa K., Davie E.W., Stoddard B.L., Thompson A.R.,
Blood 96:979-987(2000)
Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A
Roelse J.C., De Laaf R.T.M., Timmermans S.M.H., Peters M., Van Mourik J.A., Voorberg J.,
Br. J. Haematol. 108:241-246(2000)
Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family
Schwaab R., Oldenburg J., Kemball-Cook G., Albert T., Juhler C., Hanfland P., Ingerslev J.,
Br. J. Haematol. 109:523-528(2000)
Experience of a single Italian center in genetic counseling for hemophilia: from linkage analysis to molecular diagnosis
Tagariello G., Belvini D., Salviato R., Are A., De Biasi E., Goodeve A., Davoli P.,
Haematologica 85:525-529(2000)
Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate)
Recombinate PUP study group, Goodeve A.C., Williams I., Bray G.L., Peake I.R.,
Thromb. Haemost. 83:844-848(2000)
Mutations of the factor VIII gene in Thai hemophilia A patients
Akkarapatumwong V., Oranwiroon S., Pung-amritt P., Treesucon A., Thanootarakul P., Veerakul G., Mahasandana C., Panyim S., Yenchitsomanus P.,
Hum. Mutat. 15:117-118(2000)
Somatic mosaicism in hemophilia A: a fairly common event
Leuer M., Oldenburg J., Lavergne J.-M., Ludwig M., Fregin A., Eigel A., Ljung R., Goodeve A., Peake I., Olek K.,
Am. J. Hum. Genet. 69:75-87(2001)
Missense mutations causing mild hemophilia A in Iceland detected by denaturing gradient gel electrophoresis
Jonsdottir S., Diamond C., Levinson B., Magnusson S., Jensson O., Gitschier J.,
Hum. Mutat. 1:506-508(1992)
Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A
McGinniss M.J., Kazazian H.H. Jr., Hoyer L.W., Bi L., Inaba H., Antonarakis S.E.,
Genomics 15:392-398(1993)
Double strand conformation polymorphism (DSCP) detects two point mutations at codon 280 (AAC-->ATC) and at codon 431 (TAC-->AAC) of the blood coagulation factor VIII gene
Pieneman W.C., Reitsma P.H., Briet E.,
Thromb. Haemost. 69:473-475(1993)
Eleven novel mutations in the factor VIII gene from Brazilian hemophilia A patients
Arruda V.R., Pieneman W.C., Reitsma P.H., Deutz-Terlouw P.P., Annichino-Bizzacchi J.M., Brieet E., Costa F.F.,
Blood 86:3015-3020(1995)
Screening for mutations in haemophilia A patients by multiplex PCR-SSCP, Southern blotting and RNA analysis: the detection of a genetic abnormality in the factor VIII gene in 30 out of 35 patients
Pieneman W.C., Deutz-Terlouw P.P., Reitsma P.H., Brieet E.,
Br. J. Haematol. 90:442-449(1995)
Detection of mutations in ectopic factor VIII transcripts from nine haemophilia A patients and the correlation with phenotype
Bidichandani S.I., Lanyon W.G., Shiach C.R., Lowe G.D.O., Connor J.M.,
Hum. Genet. 95:531-538(1995)
Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies
Becker J., Schwaab R., Moeller-Taube A., Schwaab U., Schmidt W., Brackmann H.H., Grimm T., Olek K., Oldenburg J.,
Am. J. Hum. Genet. 58:657-670(1996)
Molecular characterization of haemophilia A in southern Chinese
Chan V., Pang A., Chan T.P.T., Chan V.W.-Y., Chan T.K.,
Br. J. Haematol. 93:451-456(1996)
Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods
Rudzki Z., Duncan E.M., Casey G.J., Neumann M., Favaloro E.J., Lloyd J.V.,
Br. J. Haematol. 94:400-406(1996)
Mutations in the FVIII gene in seven families with mild haemophilia A
Mazurier C., Gaucher C., Jorieux S., Parquet-Gernez A.,
Br. J. Haematol. 96:426-427(1997)
Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced haemophilia A patients by single-strand conformation polymorphism
Morichika S., Shima M., Kamisue S., Tanaka I., Imanaka Y., Suzuki H., Shibata H., Pemberton S., Gale K., McVey J., Tuddenham E.G.D., Yoshioka A.,
Br. J. Haematol. 98:901-906(1997)
Mutational analysis of ectopic factor VIII transcripts from hemophilia A patients: identification of cryptic splice site, exon skipping and novel point mutations
Tavassoli K., Eigel A., Pollmann H., Horst J.,
Hum. Genet. 100:508-511(1997)
Recurrent mutations and three novel rearrangements in the factor VIII gene of hemophilia A patients of Italian descent
Casula L., Murru S., Pecorara M., Ristaldi M.S., Restagno G., Mancuso G., Morfini M., de Biasi R., Baudo F., Carbonara A.,
Blood 75:662-670(1990)
CRM+ haemophilia A due to a missense mutation (372-->Cys) at the internal heavy chain thrombin cleavage site
Pattinson J.K., McVey J.H., Boon M., Ajani A., Tuddenham E.G.,
Br. J. Haematol. 75:73-77(1990)
Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA
Higuchi M., Wong C., Kochhan L., Olek K., Aronis S., Kasper C.K., Kazazian H.H. Jr., Antonarakis S.E.,
Genomics 6:65-71(1990)
Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII gene
Traystman M.D., Higuchi M., Kasper C.K., Antonarakis S.E., Kazazian H.H. Jr.,
Genomics 6:293-301(1990)
Mutations and a polymorphism in the factor VIII gene discovered by denaturing gradient gel electrophoresis
Kogan S., Gitschier J.,
Proc. Natl. Acad. Sci. U.S.A. 87:2092-2096(1990)
Identification of mutations in two families with sporadic hemophilia A
Paynton C., Sarkar G., Sommer S.S.,
Hum. Genet. 87:397-400(1991)
Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene
Higuchi M., Kazazian H.H. Jr., Kasch L., Warren T.C., McGinniss M.J., Phillips J.A. III, Kasper C., Janco R., Antonarakis S.E.,
Proc. Natl. Acad. Sci. U.S.A. 88:7405-7409(1991)
Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis
Higuchi M., Antonarakis S.E., Kasch L., Oldenburg J., Economou-Petersen E., Olek K., Arai M., Inaba H., Kazazian H.H. Jr.,
Proc. Natl. Acad. Sci. U.S.A. 88:8307-8311(1991)
Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain
Schwaab R., Ludwig M., Kochhan L., Oldenburg J., McVey J.H., Egli H., Brackmann H.H., Olek K.,
Thromb. Res. 61:225-234(1991)
GAA(Glu)272->AAA(Lys) and CGA(Arg)1941->CAA(Gln) in the factor VIII gene in two haemophilia A patients of Czech origin
Krepelova A., Vorlova Z., Acquila M., Mori P.,
Br. J. Haematol. 81:458-458(1992)
Detection of mutations in the factor VIII gene using single-stranded conformational polymorphism (SSCP)
Economou E.P., Kazazian H.H. Jr., Antonarakis S.E.,
Genomics 13:909-911(1992)
Screening for nonsense mutations in patients with severe hemophilia A can provide rapid, direct carrier detection
Reiner A.P., Thompson A.R.,
Hum. Genet. 89:88-94(1992)
A novel mutation (Arg-->Leu in exon 18) in factor VIII gene responsible for moderate hemophilia A
Nafa K., Baudis M., Deburgrave N., Bardin J.M., Sultan Y., Kaplan J.C., Delpech M.,
Hum. Mutat. 1:77-78(1992)
Amino acid substitutions in conserved domains of factor VIII and related proteins: study of patients with mild and moderately severe hemophilia A
Diamond C., Kogan S., Levinson B., Gitschier J.,
Hum. Mutat. 1:248-257(1992)
The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor
Saenko E.L., Scandella D.,
J. Biol. Chem. 272:18007-18014(1997)
Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)
McMullen B.A., Fujikawa K., Davie E.W., Hedner U., Ezban M.,
Protein Sci. 4:740-746(1995)
Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry
Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D.,
J. Proteome Res. 4:2070-2080(2005)
Membrane-binding peptide from the C2 domain of factor VIII forms an amphipathic structure as determined by NMR spectroscopy
Gilbert G.E., Baleja J.D.,
Biochemistry 34:3022-3031(1995)
The molecular basis of hemophilia A
Gitschier J.,
Ann. N. Y. Acad. Sci. 614:89-96(1991)
Factor VIII gene and hemophilia A
White G.C. II, Shoemaker C.B.,
Blood 73:1-12(1989)
Molecular etiology of factor VIII deficiency in hemophilia A
Antonarakis S.E., Kazazian H.H. Jr., Tuddenham E.G.D.,
Hum. Mutat. 5:1-22(1995)
Identification of a missense mutation in the factor VIII gene of a mild hemophiliac
Gitschier J., Wood W.I., Shuman M.A., Lawn R.M.,
Science 232:1415-1416(1986)
A novel missense mutation in the factor VIII gene identified by analysis of amplified hemophilia DNA sequences
Levinson B., Janco R.L., Phillips J.A. III, Gitschier J.,
Nucleic Acids Res. 15:9797-9805(1987)
Nonsense and missense mutations in hemophilia A: estimate of the relative mutation rate at CG dinucleotides
Youssoufian H., Antonarakis S.E., Bell W., Griffin A.M., Kazazian H.H. Jr.,
Am. J. Hum. Genet. 42:718-725(1988)
Moderately severe hemophilia A resulting from Glu-->Gly substitution in exon 7 of the factor VIII gene
Youssoufian H., Wong C., Aronis S., Platokoukis H., Kazazian H.H. Jr., Antonarakis S.E.,
Am. J. Hum. Genet. 42:867-871(1988)
Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A
O'Brien D.P., Tuddenham E.G.,
Blood 73:2117-2122(1989)
An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule
Shima M., Ware J., Yoshioka A., Fukui H., Fulcher C.A.,
Blood 74:1612-1617(1989)
A novel missense mutation in exon 4 of the factor VIII:C gene resulting in moderately severe hemophilia A
Chan V., Chan T.K., Tong T.M., Todd D.,
Blood 74:2688-2691(1989)
Mild hemophilia A resulting from Arg-to-Leu substitution in exon 26 of the factor VIII gene
Inaba H., Fujimaki M., Kazazian H.H. Jr., Antonarakis S.E.,
Hum. Genet. 81:335-338(1989)
Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372-->histidine)
Arai M., Inaba H., Higuchi M., Antonarakis S.E., Kazazian H.H. Jr., Fujimaki M., Hoyer L.W.,
Proc. Natl. Acad. Sci. U.S.A. 86:4277-4281(1989)
Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A
Arai M., Higuchi M., Antonarakis S.E., Kazazian H.H. Jr., Phillips J.A. III, Janco R.L., Hoyer L.W.,
Blood 75:384-389(1990)
Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations
Albanez S., Ruiz-Saez A., Boadas A., De Bosch N., Porco A.,
Haemophilia 17:913-918(2011)
Factor VIII Antigen, Activity, and Mutations in Hemophilia A
Nair P.S., Shetty S., Ghosh K.,
Clin. Appl. Thromb. Hemost. 22:381-385(2016)
Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity
Yada K., Nogami K., Takeyama M., Ogiwara K., Wakabayashi H., Shima M.,
J. Thromb. Haemost. 13:1843-1853(2015)
High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype-phenotype correlation
Citron M., Godmilow L., Ganguly T., Ganguly A.,
Hum. Mutat. 20:267-274(2002)
Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses
Liu M.-L., Nakaya S., Thompson A.R.,
Thromb. Haemost. 87:273-276(2002)
11 hemophilia A patients without mutations in the factor VIII encoding gene
Klopp N., Oldenburg J., Uen C., Schneppenheim R., Graw J.,
Thromb. Haemost. 88:357-360(2002)
Analysis of 18 novel mutations in the factor VIII gene
Bicocchi M.P., Pasino M., Lanza T., Bottini F., Boeri E., Mori P.G., Molinari A.C., Rosano C., Acquila M.,
Br. J. Haematol. 122:810-817(2003)
Thirty-four novel mutations detected in factor VIII gene by multiplex CSGE: modeling of 13 novel amino acid substitutions
Habart D., Kalabova D., Novotny M., Vorlova Z.,
J. Thromb. Haemost. 1:773-781(2003)
Genotype and phenotype of haemophilia A in Thai patients
Yenchitsomanus P., Akkarapatumwong V., Pung-Amritt P., Intorasoot S., Thanootarakul P., Oranwiroon S., Veerakul G., Mahasandana C.,
Haemophilia 9:179-186(2003)
Small FVIII gene rearrangements in 18 hemophilia A patients: five novel mutations
Bicocchi M.P., Pasino M., Lanza T., Bottini F., Molinari A.C., Caprino D., Rosano C., Acquila M.,
Am. J. Hematol. 78:117-122(2005)
Mutation analysis in 51 patients with haemophilia A: report of 10 novel mutations and correlations between genotype and clinical phenotype
Hill M., Deam S., Gordon B., Dolan G.,
Haemophilia 11:133-141(2005)
Female haemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII
Cai X.-H., Wang X.-F., Dai J., Fang Y., Ding Q.-L., Xie F., Wang H.-L.,
J. Thromb. Haemost. 4:1969-1974(2006)
Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites
Vencesla A., Corral-Rodriguez M.A., Baena M., Cornet M., Domenech M., Baiget M., Fuentes-Prior P., Tizzano E.F.,
Blood 111:3468-3478(2008)
Characterization of the polypeptide composition of human factor VIII:C and the nucleotide sequence and expression of the human kidney cDNA
Truett M.A., Blacher R., Burke R.L., Caput D., Chu C., Dina D., Hartog K., Kuo C.H., Masiarz F.R., Merryweather J.P., Najarian R., Pachl C., Potter S.J., Puma J., Quiroga M., Rall L.B., Randolph A., Urdea M.S., Ezban M.,
DNA 4:333-349(1985)
Expression of active human factor VIII from recombinant DNA clones
Wood W.I., Capon D.J., Simonsen C.C., Eaton D.L., Gitschier J., Keyt B., Seeburg P.H., Smith D.H., Hollingshead P., Wion K.L., Delwart E., Tuddenham E.G.D., Vehar G.A., Lawn R.M.,
Nature 312:330-337(1984)
Evidence for a third transcript from the human factor VIII gene
Levinson B., Kenwrick S., Gamel P., Fisher K., Gitschier J.,
Genomics 14:585-589(1992)
Molecular cloning of a cDNA encoding human antihaemophilic factor
Toole J.J., Knopf J.L., Wozney J.M., Sultzman L.A., Buecker J.L., Pittman D.D., Kaufman R.J., Brown E., Shoemaker C., Orr E.C., Amphlett G.W., Foster W.B., Coe M.L., Knutson G.J., Fass D.N., Hewick R.M.,
Nature 312:342-347(1984)
Sequence of the exon-containing regions of the human factor VIII gene
Gitschier J., Wood W.I.,
Hum. Mol. Genet. 1:199-200(1992)
Complete sequencing and characterization of 21,243 full-length human cDNAs
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,
Nat. Genet. 36:40-45(2004)
The DNA sequence of the human X chromosome
Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., Bentley D.R.,
Nature 434:325-337(2005)
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)
The MGC Project Team,
Genome Res. 14:2121-2127(2004)
Characterization of tyrosine sulfate residues in antihemophilic recombinant factor VIII by liquid chromatography electrospray ionization tandem mass spectrometry and amino acid analysis
Severs J.C., Carnine M., Eguizabal H., Mock K.K.,
Rapid Commun. Mass Spectrom. 13:1016-1023(1999)
Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor
Leyte A., van Schijndel H.B., Niehrs C., Huttner W.B., Verbeet M.P., Mertens K., van Mourik J.A.,
J. Biol. Chem. 266:740-746(1991)
Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII
Pittman D.D., Wang J.H., Kaufman R.J.,
Biochemistry 31:3315-3325(1992)
Characterization of the polypeptide composition of human factor VIII:C and the nucleotide sequence and expression of the human kidney cDNA.
Truett M.A., Blacher R., Burke R.L., Caput D., Chu C., Dina D., Hartog K., Kuo C.H., Masiarz F.R., Merryweather J.P., Najarian R., Pachl C., Potter S.J., Puma J., Quiroga M., Rall L.B., Randolph A., Urdea M.S., Ezban M.,
DNA 4:333-349(1985)
Expression of active human factor VIII from recombinant DNA clones.
Wood W.I., Capon D.J., Simonsen C.C., Eaton D.L., Gitschier J., Keyt B., Seeburg P.H., Smith D.H., Hollingshead P., Wion K.L., Delwart E., Tuddenham E.G.D., Vehar G.A., Lawn R.M.,
Nature 312:330-337(1984)
Evidence for a third transcript from the human factor VIII gene.
Levinson B., Kenwrick S., Gamel P., Fisher K., Gitschier J.,
Genomics 14:585-589(1992)
Molecular cloning of a cDNA encoding human antihaemophilic factor.
Toole J.J., Knopf J.L., Wozney J.M., Sultzman L.A., Buecker J.L., Pittman D.D., Kaufman R.J., Brown E., Shoemaker C., Orr E.C., Amphlett G.W., Foster W.B., Coe M.L., Knutson G.J., Fass D.N., Hewick R.M.,
Nature 312:342-347(1984)
Sequence of the exon-containing regions of the human factor VIII gene.
Gitschier J., Wood W.I.,
Hum. Mol. Genet. 1:199-200(1992)
Complete sequencing and characterization of 21,243 full-length human cDNAs.
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,
Nat. Genet. 36:40-45(2004)
The DNA sequence of the human X chromosome.
Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., Bentley D.R.,
Nature 434:325-337(2005)
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team,
Genome Res. 14:2121-2127(2004)
Characterization of tyrosine sulfate residues in antihemophilic recombinant factor VIII by liquid chromatography electrospray ionization tandem mass spectrometry and amino acid analysis.
Severs J.C., Carnine M., Eguizabal H., Mock K.K.,
Rapid Commun. Mass Spectrom. 13:1016-1023(1999)
Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor.
Leyte A., van Schijndel H.B., Niehrs C., Huttner W.B., Verbeet M.P., Mertens K., van Mourik J.A.,
J. Biol. Chem. 266:740-746(1991)
Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII.
Pittman D.D., Wang J.H., Kaufman R.J.,
Biochemistry 31:3315-3325(1992)
The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor.
Saenko E.L., Scandella D.,
J. Biol. Chem. 272:18007-18014(1997)
Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A).
McMullen B.A., Fujikawa K., Davie E.W., Hedner U., Ezban M.,
Protein Sci. 4:740-746(1995)
Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.
Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D.,
J. Proteome Res. 4:2070-2080(2005)
Membrane-binding peptide from the C2 domain of factor VIII forms an amphipathic structure as determined by NMR spectroscopy.
Gilbert G.E., Baleja J.D.,
Biochemistry 34:3022-3031(1995)
The molecular basis of hemophilia A.
Gitschier J.,
Ann. N. Y. Acad. Sci. 614:89-96(1991)
Factor VIII gene and hemophilia A.
White G.C. II, Shoemaker C.B.,
Blood 73:1-12(1989)
Molecular etiology of factor VIII deficiency in hemophilia A.
Antonarakis S.E., Kazazian H.H. Jr., Tuddenham E.G.D.,
Hum. Mutat. 5:1-22(1995)
Identification of a missense mutation in the factor VIII gene of a mild hemophiliac.
Gitschier J., Wood W.I., Shuman M.A., Lawn R.M.,
Science 232:1415-1416(1986)
A novel missense mutation in the factor VIII gene identified by analysis of amplified hemophilia DNA sequences.
Levinson B., Janco R.L., Phillips J.A. III, Gitschier J.,
Nucleic Acids Res. 15:9797-9805(1987)
Nonsense and missense mutations in hemophilia A: estimate of the relative mutation rate at CG dinucleotides.
Youssoufian H., Antonarakis S.E., Bell W., Griffin A.M., Kazazian H.H. Jr.,
Am. J. Hum. Genet. 42:718-725(1988)
Moderately severe hemophilia A resulting from Glu-->Gly substitution in exon 7 of the factor VIII gene.
Youssoufian H., Wong C., Aronis S., Platokoukis H., Kazazian H.H. Jr., Antonarakis S.E.,
Am. J. Hum. Genet. 42:867-871(1988)
Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A.
O'Brien D.P., Tuddenham E.G.,
Blood 73:2117-2122(1989)
An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.
Shima M., Ware J., Yoshioka A., Fukui H., Fulcher C.A.,
Blood 74:1612-1617(1989)
A novel missense mutation in exon 4 of the factor VIII:C gene resulting in moderately severe hemophilia A.
Chan V., Chan T.K., Tong T.M., Todd D.,
Blood 74:2688-2691(1989)
Mild hemophilia A resulting from Arg-to-Leu substitution in exon 26 of the factor VIII gene.
Inaba H., Fujimaki M., Kazazian H.H. Jr., Antonarakis S.E.,
Hum. Genet. 81:335-338(1989)
Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372-->histidine).
Arai M., Inaba H., Higuchi M., Antonarakis S.E., Kazazian H.H. Jr., Fujimaki M., Hoyer L.W.,
Proc. Natl. Acad. Sci. U.S.A. 86:4277-4281(1989)
Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.
Arai M., Higuchi M., Antonarakis S.E., Kazazian H.H. Jr., Phillips J.A. III, Janco R.L., Hoyer L.W.,
Blood 75:384-389(1990)
Recurrent mutations and three novel rearrangements in the factor VIII gene of hemophilia A patients of Italian descent.
Casula L., Murru S., Pecorara M., Ristaldi M.S., Restagno G., Mancuso G., Morfini M., de Biasi R., Baudo F., Carbonara A.,
Blood 75:662-670(1990)
CRM+ haemophilia A due to a missense mutation (372-->Cys) at the internal heavy chain thrombin cleavage site.
Pattinson J.K., McVey J.H., Boon M., Ajani A., Tuddenham E.G.,
Br. J. Haematol. 75:73-77(1990)
Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA.
Higuchi M., Wong C., Kochhan L., Olek K., Aronis S., Kasper C.K., Kazazian H.H. Jr., Antonarakis S.E.,
Genomics 6:65-71(1990)
Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII gene.
Traystman M.D., Higuchi M., Kasper C.K., Antonarakis S.E., Kazazian H.H. Jr.,
Genomics 6:293-301(1990)
Mutations and a polymorphism in the factor VIII gene discovered by denaturing gradient gel electrophoresis.
Kogan S., Gitschier J.,
Proc. Natl. Acad. Sci. U.S.A. 87:2092-2096(1990)
Identification of mutations in two families with sporadic hemophilia A.
Paynton C., Sarkar G., Sommer S.S.,
Hum. Genet. 87:397-400(1991)
Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene.
Higuchi M., Kazazian H.H. Jr., Kasch L., Warren T.C., McGinniss M.J., Phillips J.A. III, Kasper C., Janco R., Antonarakis S.E.,
Proc. Natl. Acad. Sci. U.S.A. 88:7405-7409(1991)
Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.
Higuchi M., Antonarakis S.E., Kasch L., Oldenburg J., Economou-Petersen E., Olek K., Arai M., Inaba H., Kazazian H.H. Jr.,
Proc. Natl. Acad. Sci. U.S.A. 88:8307-8311(1991)
Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain.
Schwaab R., Ludwig M., Kochhan L., Oldenburg J., McVey J.H., Egli H., Brackmann H.H., Olek K.,
Thromb. Res. 61:225-234(1991)
GAA(Glu)272->AAA(Lys) and CGA(Arg)1941->CAA(Gln) in the factor VIII gene in two haemophilia A patients of Czech origin.
Krepelova A., Vorlova Z., Acquila M., Mori P.,
Br. J. Haematol. 81:458-458(1992)
Detection of mutations in the factor VIII gene using single-stranded conformational polymorphism (SSCP).
Economou E.P., Kazazian H.H. Jr., Antonarakis S.E.,
Genomics 13:909-911(1992)
Screening for nonsense mutations in patients with severe hemophilia A can provide rapid, direct carrier detection.
Reiner A.P., Thompson A.R.,
Hum. Genet. 89:88-94(1992)
A novel mutation (Arg-->Leu in exon 18) in factor VIII gene responsible for moderate hemophilia A.
Nafa K., Baudis M., Deburgrave N., Bardin J.M., Sultan Y., Kaplan J.C., Delpech M.,
Hum. Mutat. 1:77-78(1992)
Amino acid substitutions in conserved domains of factor VIII and related proteins: study of patients with mild and moderately severe hemophilia A.
Diamond C., Kogan S., Levinson B., Gitschier J.,
Hum. Mutat. 1:248-257(1992)
Missense mutations causing mild hemophilia A in Iceland detected by denaturing gradient gel electrophoresis.
Jonsdottir S., Diamond C., Levinson B., Magnusson S., Jensson O., Gitschier J.,
Hum. Mutat. 1:506-508(1992)
Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A.
McGinniss M.J., Kazazian H.H. Jr., Hoyer L.W., Bi L., Inaba H., Antonarakis S.E.,
Genomics 15:392-398(1993)
Double strand conformation polymorphism (DSCP) detects two point mutations at codon 280 (AAC-->ATC) and at codon 431 (TAC-->AAC) of the blood coagulation factor VIII gene.
Pieneman W.C., Reitsma P.H., Briet E.,
Thromb. Haemost. 69:473-475(1993)
Eleven novel mutations in the factor VIII gene from Brazilian hemophilia A patients.
Arruda V.R., Pieneman W.C., Reitsma P.H., Deutz-Terlouw P.P., Annichino-Bizzacchi J.M., Brieet E., Costa F.F.,
Blood 86:3015-3020(1995)
Screening for mutations in haemophilia A patients by multiplex PCR-SSCP, Southern blotting and RNA analysis: the detection of a genetic abnormality in the factor VIII gene in 30 out of 35 patients.
Pieneman W.C., Deutz-Terlouw P.P., Reitsma P.H., Brieet E.,
Br. J. Haematol. 90:442-449(1995)
Detection of mutations in ectopic factor VIII transcripts from nine haemophilia A patients and the correlation with phenotype.
Bidichandani S.I., Lanyon W.G., Shiach C.R., Lowe G.D.O., Connor J.M.,
Hum. Genet. 95:531-538(1995)
Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies.
Becker J., Schwaab R., Moeller-Taube A., Schwaab U., Schmidt W., Brackmann H.H., Grimm T., Olek K., Oldenburg J.,
Am. J. Hum. Genet. 58:657-670(1996)
Molecular characterization of haemophilia A in southern Chinese.
Chan V., Pang A., Chan T.P.T., Chan V.W.-Y., Chan T.K.,
Br. J. Haematol. 93:451-456(1996)
Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods.
Rudzki Z., Duncan E.M., Casey G.J., Neumann M., Favaloro E.J., Lloyd J.V.,
Br. J. Haematol. 94:400-406(1996)
Mutations in the FVIII gene in seven families with mild haemophilia A.
Mazurier C., Gaucher C., Jorieux S., Parquet-Gernez A.,
Br. J. Haematol. 96:426-427(1997)
Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced haemophilia A patients by single-strand conformation polymorphism.
Morichika S., Shima M., Kamisue S., Tanaka I., Imanaka Y., Suzuki H., Shibata H., Pemberton S., Gale K., McVey J., Tuddenham E.G.D., Yoshioka A.,
Br. J. Haematol. 98:901-906(1997)
Mutational analysis of ectopic factor VIII transcripts from hemophilia A patients: identification of cryptic splice site, exon skipping and novel point mutations.
Tavassoli K., Eigel A., Pollmann H., Horst J.,
Hum. Genet. 100:508-511(1997)
A domain mutations in 65 haemophilia A families and molecular modelling of dysfunctional factor VIII proteins.
Liu M., Murphy M.E.P., Thompson A.R.,
Br. J. Haematol. 103:1051-1060(1998)
Protein truncation test: detection of severe haemophilia a mutation and analysis of factor VIII transcripts.
Maugard C., Tuffery S., Aguilar-Martinez P., Schved J.-F., Gris J.-C., Demaille J., Claustres M.,
Hum. Mutat. 11:18-22(1998)
Independent occurrence of the novel Arg2163 to His mutation in the factor VIII gene in three unrelated families with haemophilia A with different phenotypes.
Theophilus B.D.M., Enayat M.S., Higuchi M., Kazazian H.H. Jr., Antonarakis S.E., Hill F.G.H.,
Hum. Mutat. 11:334-334(1998)
Fluorescent chemical cleavage of mismatches for efficient screening of the factor VIII gene.
Freson K., Peerlinck K., Aguirre T., Arnout J., Vermylen J., Cassiman J.-J., Matthijs G.,
Hum. Mutat. 11:470-479(1998)
Identification of four novel mutations in the factor VIII gene: three missense mutations (E1875G, G2088S, I2185T) and a 2-bp deletion (1780delTC).
Tavassoli K., Eigel A., Dworniczak B., Valtseva E., Horst J.,
Hum. Mutat. Suppl. 1:S260-S262(1998)
Molecular diagnostics of 15 hemophilia A patients: characterization of eight novel mutations in the factor VIII gene, two of which result in exon skipping.
Tavassoli K., Eigel A., Wilke K., Pollmann H., Horst J.,
Hum. Mutat. 12:301-303(1998)
Use of denaturing gradient gel blots to screen for point mutations in the factor VIII gene.
Laprise S.L., Mak E.K., Killoran K.A., Layman L.C., Gray M.R.,
Hum. Mutat. 12:393-402(1998)
Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis.
Williams I.J., Abuzenadah A., Winship P.R., Preston F.E., Dolan G., Wright J., Peake I.R., Goodeve A.C.,
Thromb. Haemost. 79:723-726(1998)
Factor VIII inhibitors in mild and moderate-severity haemophilia A.
UK haemophilia centre directors organisation, Hay C.R.M., Ludlam C.A., Colvin B.T., Hill F.G.H., Preston F.E., Wasseem N., Bagnall R., Peake I.R., Berntorp E., Mauser Bunschoten E.P., Fijnvandraat K., Kasper C.K., White G., Santagostino E.,
Thromb. Haemost. 79:762-766(1998)
Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954-->Leu substitution in the factor VIII A3 domain.
Keeling D.M., Sukhu K., Kemball-Cook G., Waseem N., Bagnall R., Lloyd J.V.,
Br. J. Haematol. 105:1123-1126(1999)
Screen of 55 Slovenian haemophilia A patients: identification of 2 novel mutations (S-1R and IVS23+1G-->A) and discussion of mutation spectrum.
Strmecki L., Benedik-Dolnicar M., Vouk K., Komel R.,
Hum. Mutat. 13:413-413(1999)
Mutational-screening in the factor VIII gene resulting in the identification of three novel mutations, one of which is a donor splice mutation.
Moeller-Morlang K., Tavassoli K., Eigel A., Pollmann H., Horst J.,
Hum. Mutat. 13:504-504(1999)
Start of UK confidential haemophilia A database: analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch.
The haemophilia centres, Waseem N.H., Bagnall R., Green P.M., Giannelli F.,
Thromb. Haemost. 81:900-905(1999)
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Jacquemin M., Lavend'homme R., Benhida A., Vanzieleghem B., d'Oiron R., Lavergne J.-M., Brackmann H.H., Schwaab R., VandenDriessche T., Chuah M.K.L., Hoylaerts M., Gilles J.G.G., Peerlinck K., Vermylen J., Saint-Remy J.-M.R.,
Blood 96:958-965(2000)
Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.
Liu M.-L., Shen B.W., Nakaya S., Pratt K.P., Fujikawa K., Davie E.W., Stoddard B.L., Thompson A.R.,
Blood 96:979-987(2000)
Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A.
Roelse J.C., De Laaf R.T.M., Timmermans S.M.H., Peters M., Van Mourik J.A., Voorberg J.,
Br. J. Haematol. 108:241-246(2000)
Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family.
Schwaab R., Oldenburg J., Kemball-Cook G., Albert T., Juhler C., Hanfland P., Ingerslev J.,
Br. J. Haematol. 109:523-528(2000)
Experience of a single Italian center in genetic counseling for hemophilia: from linkage analysis to molecular diagnosis.
Tagariello G., Belvini D., Salviato R., Are A., De Biasi E., Goodeve A., Davoli P.,
Haematologica 85:525-529(2000)
Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate).
Recombinate PUP study group, Goodeve A.C., Williams I., Bray G.L., Peake I.R.,
Thromb. Haemost. 83:844-848(2000)
Mutations of the factor VIII gene in Thai hemophilia A patients.
Akkarapatumwong V., Oranwiroon S., Pung-amritt P., Treesucon A., Thanootarakul P., Veerakul G., Mahasandana C., Panyim S., Yenchitsomanus P.,
Hum. Mutat. 15:117-118(2000)
Somatic mosaicism in hemophilia A: a fairly common event.
Leuer M., Oldenburg J., Lavergne J.-M., Ludwig M., Fregin A., Eigel A., Ljung R., Goodeve A., Peake I., Olek K.,
Am. J. Hum. Genet. 69:75-87(2001)
Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data.
Ivaskevicius V., Jurgutis R., Rost S., Muller A., Schmitt C., Wulff K., Herrmann F.H., Muller C.R., Schwaab R., Oldenburg J.,
Br. J. Haematol. 112:1062-1070(2001)
Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A.
Theophilus B.D.M., Enayat M.S., Williams M.D., Hill F.G.H.,
Haemophilia 7:381-391(2001)
Mild haemophilia A discovered in a previously multi-operated 73-year-old man: characterization of a new mutation.
Bauduer F., Ducout L., Bendriss P., Falaises B., Lavergne J.-M.,
Haemophilia 7:419-421(2001)
Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations.
Timur A.A., Guergey A., Aktuglu G., Kavakli K., Canatan D., Olek K., Caglayan S.H.,
Haemophilia 7:475-481(2001)
Seven novel and four recurrent point mutations in the factor VIII (F8C) gene.
Bogdanova N., Lemcke B., Markoff A., Pollmann H., Dworniczak B., Eigel A., Horst J.,
Hum. Mutat. 18:546-546(2001)
Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations.
Vidal F., Farssac E., Altisent C., Puig L., Gallardo D.,
Thromb. Haemost. 85:580-583(2001)
Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A.
Valleix S., Vinciguerra C., Lavergne J.-M., Leuer M., Delpech M., Negrier C.,
Blood 100:3034-3036(2002)
Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A.
Mazurier C., Parquet-Gernez A., Gaucher C., Lavergne J.-M., Goudemand J.,
Br. J. Haematol. 119:390-392(2002)
Three novel point mutations causing haemophilia A.
Sukarova-Stefanovska E., Zisovski N., Muratovska O., Kostova S., Efremov G.D.,
Haemophilia 8:715-718(2002)
The identification and classification of 41 novel mutations in the factor VIII gene (F8C).
Cutler J.A., Mitchell M.J., Smith M.P., Savidge G.F.,
Hum. Mutat. 19:274-278(2002)
Identification of seven novel mutations of F8C by DHPLC.
Frusconi S., Passerini I., Girolami F., Masieri M., Linari S., Longo G., Morfini M., Torricelli F.,
Hum. Mutat. 20:231-232(2002)
High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype-phenotype correlation.
Citron M., Godmilow L., Ganguly T., Ganguly A.,
Hum. Mutat. 20:267-274(2002)
Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses.
Liu M.-L., Nakaya S., Thompson A.R.,
Thromb. Haemost. 87:273-276(2002)
11 hemophilia A patients without mutations in the factor VIII encoding gene.
Klopp N., Oldenburg J., Uen C., Schneppenheim R., Graw J.,
Thromb. Haemost. 88:357-360(2002)
Analysis of 18 novel mutations in the factor VIII gene.
Bicocchi M.P., Pasino M., Lanza T., Bottini F., Boeri E., Mori P.G., Molinari A.C., Rosano C., Acquila M.,
Br. J. Haematol. 122:810-817(2003)
Thirty-four novel mutations detected in factor VIII gene by multiplex CSGE: modeling of 13 novel amino acid substitutions.
Habart D., Kalabova D., Novotny M., Vorlova Z.,
J. Thromb. Haemost. 1:773-781(2003)
Genotype and phenotype of haemophilia A in Thai patients.
Yenchitsomanus P., Akkarapatumwong V., Pung-Amritt P., Intorasoot S., Thanootarakul P., Oranwiroon S., Veerakul G., Mahasandana C.,
Haemophilia 9:179-186(2003)
Small FVIII gene rearrangements in 18 hemophilia A patients: five novel mutations.
Bicocchi M.P., Pasino M., Lanza T., Bottini F., Molinari A.C., Caprino D., Rosano C., Acquila M.,
Am. J. Hematol. 78:117-122(2005)
Mutation analysis in 51 patients with haemophilia A: report of 10 novel mutations and correlations between genotype and clinical phenotype.
Hill M., Deam S., Gordon B., Dolan G.,
Haemophilia 11:133-141(2005)
Female haemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII.
Cai X.-H., Wang X.-F., Dai J., Fang Y., Ding Q.-L., Xie F., Wang H.-L.,
J. Thromb. Haemost. 4:1969-1974(2006)
Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.
Vencesla A., Corral-Rodriguez M.A., Baena M., Cornet M., Domenech M., Baiget M., Fuentes-Prior P., Tizzano E.F.,
Blood 111:3468-3478(2008)
Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations.
Albanez S., Ruiz-Saez A., Boadas A., De Bosch N., Porco A.,
Haemophilia 17:913-918(2011)
Factor VIII Antigen, Activity, and Mutations in Hemophilia A.
Nair P.S., Shetty S., Ghosh K.,
Clin. Appl. Thromb. Hemost. 22:381-385(2016)
Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K., Nogami K., Takeyama M., Ogiwara K., Wakabayashi H., Shima M.,
J. Thromb. Haemost. 13:1843-1853(2015)
Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function.
Celie P.H., Van Stempvoort G., Jorieux S., Mazurier C., Van Mourik J.A., Mertens K.,
Br J Haematol 106:792-800(1999)
Structure of the C2 domain of human factor VIII at 1.5 A resolution.
Pratt K.P., Shen B.W., Takeshima K., Davie E.W., Fujikawa K., Stoddard B.L.,
Nature 402:439-442(1999)
The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction.
Elbaz A., Poirier O., Canaple S., Chedru F., Cambien F., Amarenco P.,
Blood 95:586-591(2000)
The role of the tethering proteins p115 and GM130 in transport through the Golgi apparatus in vivo.
Seemann J., Jokitalo E.J., Warren G.,
Mol. Biol. Cell 11:635-645(2000)
Asymmetric requirements for a Rab GTPase and SNARE proteins in fusion of COPII vesicles with acceptor membranes.
Cao X., Barlowe C.,
J Cell Biol 149:55-66(2000)
COPI-coated ER-to-Golgi transport complexes segregate from COPII in close proximity to ER exit sites.
Stephens D.J., Lin-Marq N., Pagano A., Pepperkok R., Paccaud J.P.,
J Cell Sci 113:2177-2185(2000)
Rab1 recruitment of p115 into a cis-SNARE complex: programming budding COPII vesicles for fusion.
Allan B.B., Moyer B.D., Balch W.E.,
Science 289:444-448(2000)
Dynamics of transitional endoplasmic reticulum sites in vertebrate cells.
Hammond A.T., Glick B.S.,
Mol Biol Cell 11:3013-3030(2000)
Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans.
Austin H., Hooper W.C., Lally C., Dilley A., Ellingsen D., Wideman C., Wenger N.K., Rawlins P., Silva V., Evatt B.,
J Clin Epidemiol 53:997-1001(2000)
Subunit structure of a mammalian ER/Golgi SNARE complex.
Xu D., Joglekar A.P., Williams A.L., Hay J.C.,
J. Biol. Chem. 275:39631-39639(2000)
Ethnic heterogeneity of the factor XIII Val34Leu polymorphism.
Attie-Castro F.A., Zago M.A., Lavinha J., Elion J., Rodriguez-Delfin L., Guerreiro J.F., Franco R.F.,
Thromb Haemost 84:601-603(2000)
Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers.
Franco R.F., Middeldorp S., Meinardi J.R., van Pampus E.C., Reitsma P.H.,
Br J Haematol 111:118-121(2000)
Factor VIII gene polymorphisms in the Asian Indian population.
Chowdhury M.R., Herrmann F.H., Schroder W., Lambert C.T., Lalloz M.R., Layton M., Kumbnani H.K., Kabra M., Menon P.S., Verma I.C.,
Haemophilia 6:625-630(2000)
St 14 (DX S52) VNTR polymorphism in the Indian population and its application in carrier detection and prenatal diagnosis of haemophilia A families.
Shetty S., Ghosh K., Mohanty D.,
Haematologia (Budap) 30:203-207(2000)
Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.
Pipe S.W., Saenko E.L., Eickhorst A.N., Kemball-Cook G., Kaufman R.J.,
Blood 97:685-691(2001)
Rab1 interaction with a GM130 effector complex regulates COPII vesicle cis--Golgi tethering.
Moyer B.D., Allan B.B., Balch W.E.,
Traffic 2:268-276(2001)
The Golgi matrix protein GM130: a specific interacting partner of the small GTPase rab1b.
Weide T., Bayer M., Koester M., Siebrasse J.-P., Peters R., Barnekow A.,
EMBO Rep. 2:336-341(2001)
Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r)).
David D., Saenko E.L., Santos I.M., Johnson D.J., Tuddenham E.G., McVey J.H., Kemball-Cook G.,
Br J Haematol 113:604-615(2001)
A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases.
Gemmati D., Serino M.L., Ongaro A., Tognazzo S., Moratelli S., Resca R., Moretti M., Scapoli G.L.,
Am J Hematol 67:183-188(2001)
Carrier detection and prenatal diagnosis in families with haemophilia.
Shetty S., Ghosh K., Bhide A., Mohanty D.,
Natl Med J India 14:81-83(2001)
Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.
Spiegel P.C. Jr., Jacquemin M., Saint-Remy J.M., Stoddard B.L., Pratt K.P.,
Blood 98:13-19(2001)
Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion.
Boyd S., Owens D., Gin T., Bunce K., Sherafat H., Perry D., Hykin P.G.,
Br J Ophthalmol 85:1313-1315(2001)
High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene.
Kamphuisen P.W., Eikenboom J.C., Rosendaal F.R., Koster T., Blann A.D., Vos H.L., Bertina R.M.,
Br J Haematol 115:156-158(2001)
Role of factor XIII Val 34 Leu polymorphism in patients with migraine.
Iniesta J.A., Corral J., Gonzalez-Conejero R., Diaz Ortuno A., Martinez Navarro M.L., Vicente V.,
Cephalalgia 21:837-841(2001)
Role of factor XIII Val34Leu polymorphism in retinal artery occlusion.
Weger M., Renner W., Stanger O., Schmut O., Deutschmann H., Wascher T.C., Haas A.,
Stroke 32:2759-2761(2001)
The significance of nucleotide repeat sequences in FVIII gene for detecting hemophilia A carriers.
Long G., Zhu C., Liu J.,
Zhonghua Xue Ye Xue Za Zhi 22:511-513(2001)
Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg336.
Koszelak Rosenblum M.E., Schmidt K., Freas J., Mastri M., Fay P.J.,
J Biol Chem 277:11664-11669(2002)
3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography.
Stoilova-McPhie S., Villoutreix B.O., Mertens K., Kemball-Cook G., Holzenburg A.,
Blood 99:1215-1223(2002)
Absence of mutations at the APC interacting sites of factor VIII in Caucasians.
Brummer J., Groth J., Flayeh R., Wagener C., Jung R.,
Thromb Haemost 87:170-170(2002)
A founder factor VIII mutation, valine 2016 to alanine, in a population with an extraordinarily high prevalence of mild hemophilia A.
Xie Y.G., Zheng H., Leggo J., Scully M.F., Lillicrap D.,
Thromb Haemost 87:178-179(2002)
Molecular basis for different ability of low-density and high-density lipoproteins to support activity of the intrinsic Xase complex.
Khrenov A., Sarafanov A., Ananyeva N., Kouiavskaia D., Shima M., Schwinn H., Josic D., Saenko E.,
Thromb Res 105:87-93(2002)
Sequential tethering of Golgins and catalysis of SNAREpin assembly by the vesicle-tethering protein p115.
Shorter J., Beard M.B., Seemann J., Dirac-Svejstrup A.B., Warren G.,
J. Cell Biol. 157:45-62(2002)
No association of factor XIII Val34Leu polymorphism with primary intracerebral hemorrhage and healthy controls in Korean population.
Cho K.H., Kim B.C., Kim M.K., Shin B.A.,
J Korean Med Sci 17:249-253(2002)
Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque.
Ananyeva N.M., Kouiavskaia D.V., Shima M., Saenko E.L.,
Blood 99:4475-4485(2002)
Mutations at the activated protein C cleavage sites Arg336 and Arg562 of factor VIII in Thai patients with venous thrombosis.
Prayoonwiwat W., Arnutti P., Nathalang O., Suwanasophon C., Viputtigul K.,
Southeast Asian J Trop Med Public Health 32:880-883(2001)
Effect of factor VIII deficiency on generation of thrombin: a biomechanical approach.
Obraztsov I.F., Kuz'min V.M., Khanin M.A., Kogan A.E., Anan'eva N.M., Saenko E.L.,
Dokl Biochem Biophys 383:119-121(2002)
Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.
Jenkins P.V., Freas J., Schmidt K.M., Zhou Q., Fay P.J.,
Blood 100:501-508(2002)
First molecular characterization of an unequal homologous alu-mediated recombination event responsible for hemophilia.
Vidal F., Farssac E., Tusell J., Puig L., Gallardo D.,
Thromb Haemost 88:12-16(2002)
Molecular defects in coagulation Factor VIII and their impact on Factor VIII function.
Saenko E.L., Ananyeva N., Kouiavskaia D., Schwinn H., Josic D., Shima M., Hauser C.A., Pipe S.,
Vox Sang 83:89-96(2002)
Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A.
Bogdanova N., Markoff A., Pollmann H., Nowak-Gottl U., Eisert R., Dworniczak B., Eigel A., Horst J.,
Hum Mutat 20:236-237(2002)
Coordinate binding studies of the substrate (factor X) with the cofactor (factor VIII) in the assembly of the factor X activating complex on the activated platelet surface.
Ahmad S.S., Walsh P.N.,
Biochemistry 41:11269-11276(2002)
Sec16p potentiates the action of COPII proteins to bud transport vesicles.
Supek F., Madden D.T., Hamamoto S., Orci L., Schekman R.W.,
J. Cell Biol. 158:1029-1038(2002)
Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis.
Van Hylckama Vlieg A., Komanasin N., Ariens R.A., Poort S.R., Grant P.J., Bertina R.M., Rosendaal F.R.,
Br J Haematol 119:169-175(2002)
Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
Libourel E.J., Bank I., Meinardi J.R., Balje -Volkers C.P., Hamulyak K., Middeldorp S., Koopman M.M., van Pampus E.C., Prins M.H., Buller H.R., van der Meer J.,
Haematologica 87:1068-1073(2002)
Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.
Hakeos W.H., Miao H., Sirachainan N., Kemball-Cook G., Saenko E.L., Kaufman R.J., Pipe S.W.,
Thromb Haemost 88:781-787(2002)
Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.
Bovenschen N., Boertjes R.C., van Stempvoort G., Voorberg J., Lenting P.J., Meijer A.B., Mertens K.,
J Biol Chem 278:9370-9377(2003)
2% Haemophilia A patients without mutation in the FVIII gene.
Uen C., Oldenburg J., Schroder J., Brackmann H.J., Schramm W., Schwaab R., Schneppenheim R., Graw J.,
Hamostaseologie 23:1-5(2003)
Effect of factor VIII on tissue factor-initiated spatial clot growth.
Ovanesov M.V., Lopatina E.G., Saenko E.L., Ananyeva N.M., Ul'yanova L.I., Plyushch O.P., Butilin A.A., Ataullakhanov F.I.,
Thromb Haemost 89:235-242(2003)
Study on the Polymorphism of Intron 22 (CA)n Repeat within FVIII Gene in Dai, Yi and Han Populations of Yunnan Province.
Tai H., Dian Z., Ouyang H., Li Z., Wan H., Ruan C.,
Zhongguo Shi Yan Xue Ye Xue Za Zhi 8:142-144(2000)
No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.
Molecular characterization of the immune response to factor VIII.
Lollar P.,
Vox Sang 83 Suppl 1:403-408(2002)
Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex.
Zhang B., Cunningham M.A., Nichols W.C., Bernat J.A., Seligsohn U., Pipe S.W., McVey J.H., Schulte-Overberg U., de Bosch N.B., Ruiz-Saez A., White G.C., Tuddenham E.G., Kaufman R.J., Ginsburg D.,
Nat. Genet. 34:220-225(2003)
The preparation and phospholipid binding property of the C2 domain of human factor VIII.
Takeshima K., Smith C., Tait J., Fujikawa K.,
Thromb Haemost 89:788-794(2003)
Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.
Lewis D.A., Pound M.L., Ortel T.L.,
Thromb Haemost 89:795-802(2003)
Prenatal diagnosis in hemophilia A using factor VIII gene polymorphism--Indian experience.
Chowdhury M.R., Tiwari M., Kabra M., Menon P.S.,
Ann Hematol 82:427-430(2003)
Analysis of large structural changes of the factor VIII gene, involving intron 1 and 22, in severe hemophilia A.
Andrikovics H., Klein I., Bors A., Nemes L., Marosi A., Varadi A., Tordai A.,
Haematologica 88:778-784(2003)
Genetic risk factors for cerebrovascular disease in children with sickle cell disease: design of a case-control association study and genomewide screen.
Adams G.T., Snieder H., McKie V.C., Clair B., Brambilla D., Adams R.J., Kutlar F., Kutlar A.,
BMC Med Genet 4:6-6(2003)
Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor.
Raut S., Villard S., Grailly S., Gilles J.G., Granier C., Saint-Remy J.M., Barrowcliffe T.W.,
Thromb Haemost 90:385-397(2003)
Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.
d'Oiron R., Lavergne J.M., Lavend'homme R., Benhida A., Bordet J.C., Negrier C., Peerlinck K., Vermylen J., Saint-Remy J.M., Jacquemin M.,
Blood 103:155-157(2004)
Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX.
Ludwig M., Sabharwal A.K., Brackmann H.H., Olek K., Smith K.J., Birktoft J.J., Bajaj S.P.,
Blood 79:1225-1232(1992)
Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium.
Sanchez-Luceros A., Meschengieser S.S., Marchese C., Votta R., Casais P., Woods A.I., Nadal M.V., Salviu M.J., Lazzari M.A.,
Blood Coagul Fibrinolysis 14:647-651(2003)
Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI.
Lavigne G., Mercier E., Quere I., Dauzat M., Gris J.C.,
J Thromb Haemost 1:2134-2139(2003)
Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface.
Ahmad S.S., London F.S., Walsh P.N.,
J Thromb Haemost 1:2348-2355(2003)
LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII.
Cunningham M.A., Pipe S.W., Zhang B., Hauri H.P., Ginsburg D., Kaufman R.J.,
J Thromb Haemost 1:2360-2367(2003)
Persistent high factor VIII:C in a child with ischemic stroke.
Rauch R., Girisch M., Hertzberg H., Klinge J., Hofbeck M.,
Thromb Res 111:51-54(2003)
Elevated plasma levels of factor VIII in women with early recurrent miscarriage.
Marietta M., Facchinetti F., Sgarbi L., Simoni L., Bertesi M., Torelli G., Volpe A.,
J Thromb Haemost 1:2536-2539(2003)
Activation of factor VIII and mechanisms of cofactor action.
Fay P.J.,
Blood Rev 18:1-15(2004)
Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study.
Hefler L., Jirecek S., Heim K., Grimm C., Antensteiner G., Zeillinger R., Husslein P., Tempfer C.,
J Soc Gynecol Investig 11:42-44(2004)
The factor VIII gene intron 1 inversion mutation: prevalence in severe hemophilia A patients in the UK.
Cumming A.M.,
J Thromb Haemost 2:205-206(2004)
Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain.
Nogami K., Lapan K.A., Zhou Q., Wakabayashi H., Fay P.J.,
J Biol Chem 279:15763-15771(2004)
Factor VIII expression in liver disease.
Hollestelle M.J., Geertzen H.G., Straatsburg I.H., van Gulik T.M., van Mourik J.A.,
Thromb Haemost 91:267-275(2004)
Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.
Parker E.T., Healey J.F., Barrow R.T., Craddock H.N., Lollar P.,
Blood 104:704-710(2004)
Effect of factor VIIIc levels in pediatric stroke patients.
Cangoz E., Deda G., Akar N.,
Pediatr Hematol Oncol 21:255-260(2004)
High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII.
Schambeck C.M., Grossmann R., Zonnur S., Berger M., Teuchert K., Spahn A., Walter U.,
Thromb Haemost 92:42-46(2004)
Production of transgenic chimeric rabbits and transmission of the transgene through the germline.
Bodo S., Gocza E., Revay T., Hiripi L., Carstea B., Kovacs A., Bodrogi L., Bosze Z.,
Mol Reprod Dev 68:435-440(2004)
Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII.
Reding M.T., Okita D.K., Diethelm-Okita B.M., Anderson T.A., Conti-Fine B.M.,
J Thromb Haemost 2:1385-1394(2004)
High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11.
Berger M., Mattheisen M., Kulle B., Schmidt H., Oldenburg J., Bickeboller H., Walter U., Lindner T.H., Strauch K., Schambeck C.M.,
Blood 105:638-644(2005)
Fibrin stimulates platelets to increase factor VIIIa binding site expression.
Phillips J.E., Lord S.T., Gilbert G.E.,
J Thromb Haemost 2:1806-1815(2004)
Von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions.
Tomokiyo K., Kamikubo Y., Hanada T., Araki T., Nakatomi Y., Ogata Y., Jung S.M., Nakagaki T., Moroi M.,
Blood 105:1078-1084(2005)
Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities.
Spiegel P.C., Murphy P., Stoddard B.L.,
J Biol Chem 279:53691-53698(2004)
T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects.
Hu G.L., Okita D.K., Conti-Fine B.M.,
J Thromb Haemost 2:1908-1917(2004)
Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis.
Bank I., Libourel E.J., Middeldorp S., Hamulyak K., van Pampus E.C., Koopman M.M., Prins M.H., van der Meer J., Buller H.R.,
J Thromb Haemost 3:79-84(2005)
Identification of new dinucleotide-repeat polymorphisms in factor VIII gene using fluorescent PCR.
Kim J.W., Park S.Y., Kim Y.M., Kim J.M., Kim D.J., Ryu H.M.,
Haemophilia 11:38-42(2005)
Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene.
El-Maarri O., Herbiniaux U., Graw J., Schroder J., Terzic A., Watzka M., Brackmann H.H., Schramm W., Hanfland P., Schwaab R., Muller C.R., Oldenburg J.,
J Thromb Haemost 3:332-339(2005)
Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site.
Nogami K., Zhou Q., Wakabayashi H., Fay P.J.,
Blood 105:4362-4368(2005)
Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A.
Ahmed R.P., Ivaskevicius V., Kannan M., Seifried E., Oldenburg J., Saxena R.,
Haematologica 90:283-284(2005)
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels.
Scanavini D., Legnani C., Lunghi B., Mingozzi F., Palareti G., Bernardi F.,
Thromb Haemost 93:453-456(2005)
The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.
Tirado I., Mateo J., Soria J.M., Oliver A., Martinez-Sanchez E., Vallve C., Borrell M., Urrutia T., Fontcuberta J.,
Thromb Haemost 93:468-474(2005)
Thrombophilic polymorphisms and intrauterine growth restriction.
Infante-Rivard C., Rivard G.E., Guiguet M., Gauthier R.,
Epidemiology 16:281-287(2005)
The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level.
Vossen C.Y., Rosendaal F.R.,
J Thromb Haemost 3:1102-1103(2005)
LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway.
Zhang B., Kaufman R.J., Ginsburg D.,
J Biol Chem 280:25881-25886(2005)
Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.
Schmidt A.E., Stewart J.E., Mathur A., Krishnaswamy S., Bajaj S.P.,
J Mol Biol 350:78-91(2005)
The spectrum of mutations in Southern Spanish patients with hemophilia A and identification of 28 novel mutations.
Fernandez-Lopez O., Garcia-Lozano J.R., Nunez-Vazquez R., Perez-Garrido R., Nunez-Roldan A.,
Haematologica 90:707-710(2005)
Exon skipping partially restores factor VIII coagulant activity in patients with mild hemophilia A with exon 13 duplication.
Acquila M., Pasino M., Lanza T., Molinari A.C., Rosano C., Bicocchi M.P.,
Haematologica 90:997-999(2005)
Identification of a novel immunodominant cytotoxic T lymphocyte epitope derived from human factor VIII in a murine model of hemophilia A.
Wang W., Merchlinsky M., Inman J., Golding B.,
Thromb Res 116:335-344(2005)
A Glu113Ala mutation within a factor VIII Ca2+-binding site enhances cofactor interactions in factor Xase.
Wakabayashi H., Su Y.C., Ahmad S.S., Walsh P.N., Fay P.J.,
Biochemistry 44:10298-10304(2005)
Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A.
Bogdanova N., Markoff A., Pollmann H., Nowak-Gottl U., Eisert R., Wermes C., Todorova A., Eigel A., Dworniczak B., Horst J.,
Hum Mutat 26:249-254(2005)
Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J., Skulimowska J., Windyga J., Lopaciuk S., Koscielak J.,
Arch Immunol Ther Exp (Warsz) 53:352-356(2005)
Molecular models of the procoagulant factor VIIIa-factor IXa complex.
Autin L., Miteva M.A., Lee W.H., Mertens K., Radtke K.P., Villoutreix B.O.,
J Thromb Haemost 3:2044-2056(2005)
Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions.
Jayandharan G., Shaji R.V., Baidya S., Nair S.C., Chandy M., Srivastava A.,
Haemophilia 11:481-491(2005)
Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa.
Fay P.J., Smudzin T.M.,
J Biol Chem 267:13246-13250(1992)
Anti-factor VIII antibodies: a 2005 update.
Lavigne-Lissalde G., Schved J.F., Granier C., Villard S.,
Thromb Haemost 94:760-769(2005)
Cysteine-disulfide cross-linking to monitor SNARE complex assembly during endoplasmic reticulum-Golgi transport.
Flanagan J.J., Barlowe C.,
J Biol Chem 281:2281-2288(2006)
Lack of F8 mRNA: a novel mechanism leading to hemophilia A.
El-Maarri O., Singer H., Klein C., Watzka M., Herbiniaux U., Brackmann H.H., Schroder J., Graw J., Muller C.R., Schramm W., Schwaab R., Haaf T., Hanfland P., Oldenburg J.,
Blood 107:2759-2765(2006)
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.
Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A.K.,
Blood 107:3167-3172(2006)
The protein structure and effect of factor VIII.
Fang H., Wang L., Wang H.,
Thromb Res 119:1-13(2007)
A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation.
Parker E.T., Doering C.B., Lollar P.,
J Biol Chem 281:13922-13930(2006)
FVIII production by human lung microvascular endothelial cells.
Jacquemin M., Neyrinck A., Hermanns M.I., Lavend'homme R., Rega F., Saint-Remy J.M., Peerlinck K., Van Raemdonck D., Kirkpatrick C.J.,
Blood 108:515-517(2006)
Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations.
Vinciguerra C., Zawadzki C., Dargaud Y., Pernod G., Berger C., Nougier C., Negrier C.,
Thromb Haemost 95:593-599(2006)
Haemophilia A in a female caused by coincidence of a Swyer syndrome and a missense mutation in factor VIII gene.
Loreth R.M., El-Maarri O., Schroder J., Budde U., Herrmann F.H., Oldenburg J.,
Thromb Haemost 95:747-748(2006)
On and off membrane dynamics of the endoplasmic reticulum-golgi tethering factor p115 in vivo.
Brandon E., Szul T., Alvarez C., Grabski R., Benjamin R., Kawai R., Sztul E.,
Mol Biol Cell 17:2996-3008(2006)
Allele frequencies of three factor VIII gene polymorphisms in Iranian populations and their application in hemophilia A carrier detection.
Azimifar S.B., Seyedna S.Y., Zeinali S.,
Am J Hematol 81:335-339(2006)
Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis.
Nossent A.Y., Eikenboom J.C., Vos H.L., Bakker E., Tanis B.C., Doggen C.J., Bertina R.M., Rosendaal F.R.,
Thromb Haemost 95:942-948(2006)
The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients.
David D., Ventura C., Moreira I., Diniz M.J., Antunes M., Tavares A., Araujo F., Morais S., Campos M., Lavinha J., Kemball-Cook G.,
Haematologica 91:840-843(2006)
Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.
Guillet B., Lambert T., d'Oiron R., Proulle V., Plantier J.L., Rafowicz A., Peynet J., Costa J.M., Bendelac L., Laurian Y., Lavergne J.M.,
Hum Mutat 27:676-685(2006)
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q., Wilcox D.A., Fahs S.A., Weiler H., Wells C.W., Cooley B.C., Desai D., Morateck P.A., Gorski J., Montgomery R.R.,
J Clin Invest 116:1974-1982(2006)
Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain.
Bovenschen N., van Stempvoort G., Voorberg J., Mertens K., Meijer A.B.,
J Thromb Haemost 4:1487-1493(2006)
Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A.
Kiss F., Hevessy Z., Veszpremi A., Katona E., Kiss C., Vereb G., Muszbek L., Kappelmayer J.N.,
Thromb Haemost 96:176-182(2006)
Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells.
Jiang X., Guo Y.L., Bromberg M.E.,
Thromb Haemost 96:196-201(2006)
Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
Hilbert L., Nurden P., Caron C., Nurden A.T., Goudemand J., Meyer D., Fressinaud E., Mazurier C.,
Thromb Haemost 96:290-294(2006)
Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.
Pfistershammer K., Stockl J., Siekmann J., Turecek P.L., Schwarz H.P., Reipert B.M.,
Thromb Haemost 96:309-316(2006)
Contribution of low density lipoprotein receptor-related protein genotypes to coagulation factor VIII levels in thrombotic women.
Marchetti G., Lunghi B., Legnani C., Cini M., Pinotti M., Mascoli F., Bernard F.,
Haematologica 91:1261-1263(2006)
Sec16 defines endoplasmic reticulum exit sites and is required for secretory cargo export in mammalian cells.
Watson P., Townley A.K., Koka P., Palmer K.J., Stephens D.J.,
Traffic 7:1678-1687(2006)
Cargo selectivity of the ERGIC-53/MCFD2 transport receptor complex.
Nyfeler B., Zhang B., Ginsburg D., Kaufman R.J., Hauri H.P.,
Traffic 7:1473-1481(2006)
SNARE status regulates tether recruitment and function in homotypic COPII vesicle fusion.
Bentley M., Liang Y., Mullen K., Xu D., Sztul E., Hay J.C.,
J Biol Chem 281:38825-38833(2006)
Increased levels of coagulation factor VIII in internal carotid artery occlusion.
Paparounas K., Gotsi A., Galiatsou E., Kitsos A., Akritidis N.,
Eur J Neurol 13:e7-8(2006)
von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.
Chauhan A.K., Kisucka J., Lamb C.B., Bergmeier W., Wagner D.D.,
Blood 109:2424-2429(2007)
Two mammalian Sec16 homologues have nonredundant functions in endoplasmic reticulum (ER) export and transitional ER organization.
Bhattacharyya D., Glick B.S.,
Mol. Biol. Cell 18:839-849(2007)
Increased factor VIII coagulant activity levels in male carriers of the factor V R2 polymorphism.
Martinelli N., Girelli D., Ferraresi P., Olivieri O., Lunghi B., Manzato F., Corrocher R., Bernardi F.,
Blood Coagul Fibrinolysis 18:125-129(2007)
TRAPPI tethers COPII vesicles by binding the coat subunit Sec23.
Cai H., Yu S., Menon S., Cai Y., Lazarova D., Fu C., Reinisch K., Hay J.C., Ferro-Novick S.,
Nature 445:941-944(2007)
Mechanisms of COPII vesicle formation and protein sorting.
Sato K., Nakano A.,
FEBS Lett 581:2076-2082(2007)
Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis.
Voko Z., Bereczky Z., Katona E., Adany R., Muszbek L.,
Thromb Haemost 97:458-463(2007)
Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females.
Renault N.K., Dyack S., Dobson M.J., Costa T., Lam W.L., Greer W.L.,
Eur J Hum Genet 15:628-637(2007)
[A study on the (CA)n in FVIII gene in Han ethnic group in Guangxi Zhuang Autonomous Region by amplification polymorphisms combined with silver staining].
Zhu C.J., Liu J.Z., Ou W.L., Long G.F., Liang Y., Wang Z.Y., Zheng M.C.,
Zhonghua Er Ke Za Zhi 45:55-58(2007)
Large-scale mapping of human protein-protein interactions by mass spectrometry.
Ewing R.M., Chu P., Elisma F., Li H., Taylor P., Climie S., McBroom-Cerajewski L., Robinson M.D., O'Connor L., Li M., Taylor R., Dharsee M., Ho Y., Heilbut A., Moore L., Zhang S., Ornatsky O., Bukhman Y.V., Figeys D.,
Mol Syst Biol 3:89-89(2007)
Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.
Repesse Y., Slaoui M., Ferrandiz D., Gautier P., Costa C., Costa J.M., Lavergne J.M., Borel-Derlon A.,
J Thromb Haemost 5:1469-1476(2007)
Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene.
Castaman G., Giacomelli S.H., Ghiotto R., Boseggia C., Pojani K., Bulo A., Madeo D., Rodeghiero F.,
Haemophilia 13:311-316(2007)
Identification of factor VIII gene mutations and carrier detection in Korean haemophilia A patients.
Han J.Y., Lee J.N., Lee S.Y., Kim I.J., Kim C.M.,
Haemophilia 13:331-333(2007)
A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.
Dasgupta S., Navarrete A.M., Bayry J., Delignat S., Wootla B., Andre S., Christophe O., Nascimbeni M., Jacquemin M., Martinez-Pomares L., Geijtenbeek T.B., Moris A., Saint-Remy J.M., Kazatchkine M.D., Kaveri S.V., Lacroix-Desmazes S.,
Proc Natl Acad Sci U S A 104:8965-8970(2007)
F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors.
Salviato R., Belvini D., Radossi P., Sartori R., Pierobon F., Zanotto D., Zanon E., Castaman G., Gandini G., Tagariello G.,
Haemophilia 13:361-372(2007)
Factor VIII levels in children with ischemic stroke.
Duran R., Biner B., Demir M.,
Clin Appl Thromb Hemost 13:334-335(2007)
[Effect of L-arginine on human coagulant factor VIII gene expression].
Yin J., Shi G.G., Zheng Q.T., Zeng Y., Yao G.F., Lu P.W., Wang X.F., Wang H.,
Zhonghua Xue Ye Xue Za Zhi 28:178-183(2007)
Duplications involving int22h-1 of the factor VIII gene: a cause for concern in genetic testing for hemophilia A?
Green P., Hill M., Bowen D.J.,
J Thromb Haemost 5:2155-2156(2007)
[Application study on inversion diagnosis of F8 gene in hemophilia A].
Qi L.Y., Jin C.L., Lin C.K., Ren M.H., Dong W.H., Sun K.L.,
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24:405-408(2007)
Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G., Franchini M., Salvagno G.L., Montagnana M., Poli G., Guidi G.C.,
J Thromb Thrombolysis 26:150-153(2008)
Recurrent inversion with concomitant deletion and insertion events in the coagulation factor VIII gene suggests a new mechanism for X-chromosomal rearrangements causing hemophilia A.
Muhle C., Zenker M., Chuzhanova N., Schneider H.,
Hum Mutat 28:1045-1045(2007)
Long-term expression of von Willebrand Factor by a VSV-G pseudotyped lentivirus enhances the functional activity of secreted B-Domain-deleted Coagulation Factor VIII.
Park S.W., Choi S.Y.,
Mol Cells 24:125-131(2007)
Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
Meeks S.L., Healey J.F., Parker E.T., Barrow R.T., Lollar P.,
Blood 110:4234-4242(2007)
Activated protein C resistance test using factor VIII-deficient plasma: a new approach to the venous thrombotic risk?
Andre E., Hacquard M., Alnot Y., de Maistre E., Lecompte T.,
Thromb Haemost 98:693-694(2007)
Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Mahieu B., Jacobs N., Mahieu S., Naelaerts K., Vertessen F., Weyler J., Jacquemyn Y., Van der Planken M.,
Blood Coagul Fibrinolysis 18:685-688(2007)
The factor VIII C1 domain contributes to platelet binding.
Hsu T.C., Pratt K.P., Thompson A.R.,
Blood 111:200-208(2008)
Variation in 24 hemostatic genes and associations with non-fatal myocardial infarction and ischemic stroke.
Smith N.L., Bis J.C., Biagiotti S., Rice K., Lumley T., Kooperberg C., Wiggins K.L., Heckbert S.R., Psaty B.M.,
J Thromb Haemost 6:45-53(2008)
Characterization of a causative mutation of hemophilia A identified in the promoter region of the factor VIII gene (F8).
Dai L., Cutler J.A., Savidge G.F., Mitchell M.J.,
J Thromb Haemost 6:193-195(2008)
Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies.
van den Biggelaar M., Bierings R., Storm G., Voorberg J., Mertens K.,
J Thromb Haemost 5:2235-2242(2007)
The tertiary structure and domain organization of coagulation factor VIII.
Shen B.W., Spiegel P.C., Chang C.H., Huh J.W., Lee J.S., Kim J., Kim Y.H., Stoddard B.L.,
Blood 111:1240-1247(2008)
Analysing two dinucleotide repeats of FVIII gene in Iranian population.
Rabbani B., Rezaeian A., Khanahmad H., Bagheri R., Kamali E., Zeinali S.,
Haemophilia 13:740-744(2007)
Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.
Shovlin C.L., Sulaiman N.L., Govani F.S., Jackson J.E., Begbie M.E.,
Thromb Haemost 98:1031-1039(2007)
Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study.
Bank I., van de Poel M.H., Coppens M., Hamulyak K., Prins M.H., van der Meer J., Veeger N.J., Buller H.R., Middeldorp S.,
Thromb Haemost 98:1040-1044(2007)
Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S., Dasgupta S., Andre S., Navarrete A.M., Kaveri S.V., Bayry J., Andre M.H., Chtourou S., Tellier Z., Lacroix-Desmazes S.,
Haematologica 92:1423-1426(2007)
Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?
Lyall H., Hill M., Westby J., Grimley C., Dolan G.,
Haemophilia 14:78-80(2008)
Localization of the low-density lipoprotein receptor-related protein regions involved in binding to the A2 domain of coagulation factor VIII.
Sarafanov A.G., Makogonenko E.M., Andersen O.M., Mikhailenko I.A., Ananyeva N.M., Khrenov A.V., Shima M., Strickland D.K., Saenko E.L.,
Thromb Haemost 98:1170-1181(2007)
Factor VIII gene haplotypes and linkage disequilibrium for the indirect genetic analysis of hemophilia A in India.
Singh M., Singh P.,
Clin Appl Thromb Hemost 15:334-339(2009)
In vitro cultured progenitors and precursors of cardiac cell lineages from human normal and post-ischemic hearts.
Di Meglio F., Nurzynska D., Castaldo C., Arcucci A., De Santo L., de Feo M., Cotrufo M., Montagnani S., Giordano-Lanza G.,
Eur J Histochem 51:275-282(2007)
Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.
Dasgupta S., Navarrete A.M., Andre S., Wootla B., Delignat S., Repesse Y., Bayry J., Nicoletti A., Saenko E.L., d'Oiron R., Jacquemin M., Saint-Remy J.M., Kaveri S.V., Lacroix-Desmazes S.,
Haematologica 93:83-89(2008)
A recurrent F8 mutation in Irish haemophilia A patients: evidence for a founder effect.
Winter P.C., Egan H., McNulty O., Jones F.G., O'Donnell J., Jenkins P.V.,
Haemophilia 14:394-395(2008)
Cathepsin G, a leukocyte protease, activates coagulation factor VIII.
Gale A.J., Rozenshteyn D.,
Thromb Haemost 99:44-51(2008)
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R., Santagostino E., Faradji A., Iorio A., van der Meer J., Ingerslev J., Lambert T., Maas-Enriquez M., Gorina E.,
Thromb Haemost 99:52-58(2008)
Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A.
Santacroce R., Acquila M., Belvini D., Castaldo G., Garagiola I., Giacomelli S.H., Lombardi A.M., Minuti B., Riccardi F., Salviato R., Tagliabue L., Grandone E., Margaglione M.,
J Hum Genet 53:275-284(2008)
The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII.
Ananyeva N.M., Makogonenko Y.M., Kouiavskaia D.V., Ruiz J., Limburg V., Meijer A.B., Khrenov A.V., Shima M., Strickland D.K., Saenko E.L.,
Blood Coagul Fibrinolysis 19:166-177(2008)
Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F., Taketomi T., Sheppard C.A., Kempton C.L., Levy J.H., Tanaka K.A.,
Anesth Analg 106:719-724(2008)
Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.
Wakabayashi H., Fay P.J.,
J Biol Chem 283:11645-11651(2008)
The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis.
Albert T., Egler C., Jakuschev S., Schuldenzucker U., Schmitt A., Brokemper O., Zabe-Kuhn M., Hoffmann D., Oldenburg J., Schwaab R.,
Thromb Haemost 99:634-637(2008)
Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.
Planque S., Escobar M.A., Smith K.C., Taguchi H., Nishiyama Y., Donnachie E., Pratt K.P., Paul S.,
J Biol Chem 283:11876-11886(2008)
The spectrum of the factor 8 (F8) defects in Taiwanese patients with haemophilia A.
Ma G.C., Chang S.P., Chen M., Kuo S.J., Chang C.S., Shen M.C.,
Haemophilia 14:787-795(2008)
Spectrum of factor VIII mutations in Arab patients with severe haemophilia A.
Abu-Amero K.K., Hellani A., Al-Mahed M., Al-Sheikh I.,
Haemophilia 14:484-488(2008)
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype.
Margaglione M., Castaman G., Morfini M., Rocino A., Santagostino E., Tagariello G., Tagliaferri A.R., Zanon E., Bicocchi M.P., Castaldo G., Peyvandi F., Santacroce R., Torricelli F., Grandone E., Mannucci P.M.,
Haematologica 93:722-728(2008)
Persistent factor VIII-dependent factor X activation on endothelial cells is independent of von Willebrand factor.
Brinkman H.J., van Mourik J.A., Mertens K.,
Blood Coagul Fibrinolysis 19:190-196(2008)
Screening of mutations of hemophilia A in 40 Italian patients: a novel G-to-A mutation in intron 10 of the F8 gene as a putative cause of mild hemophilia A in southern Italy.
Santacroce R., Santoro R., Sessa F., Iannaccaro P., Sarno M., Longo V., Gallone A., Vecchione G., Muleo G., Margaglione M.,
Blood Coagul Fibrinolysis 19:197-202(2008)
Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.
Ngo J.C., Huang M., Roth D.A., Furie B.C., Furie B.,
Structure 16:597-606(2008)
Severe and moderate hemophilia A: identification of 38 new genetic alterations.
Casana P., Cabrera N., Cid A.R., Haya S., Beneyto M., Espinos C., Cortina V., Dasi M.A., Aznar J.A.,
Haematologica 93:1091-1094(2008)
Founder haplotype associated with the factor VIII Asp1241Glu polymorphism in a cohort of mild hemophilia A patients.
Casana P., Martinez F., Cabrera N., Cid A.R., Aznar J.A.,
J Thromb Haemost 6:1428-1430(2008)
Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V.
Gale A.J., Cramer T.J., Rozenshteyn D., Cruz J.R.,
J Biol Chem 283:16355-16362(2008)
Binding of recombinant human coagulation factor VIII to lipid nanotubes.
Parmenter C.D., Stoilova-McPhie S.,
FEBS Lett 582:1657-1660(2008)
Common polymorphisms and cardiovascular factors in patients with myocardial infarction of Costa Rica.
Salazar-Sanchez L., Chaves L., Cartin M., Schuster G., Wulff K., Schroder W., Herrmann F.H.,
Rev Biol Trop 54:1-11(2006)
Mutational spectrum of F8 gene and prothrombotic gene variants in haemophilia A patients from Southern Italy.
Sanna V., Zarrilli F., Nardiello P., D'Argenio V., Rocino A., Coppola A., DI Minno G., Castaldo G.,
Haemophilia 14:796-803(2008)
Molecular analysis of F8 in Lebanese haemophilia A patients: novel mutations and phenotype-genotype correlation.
Djambas Khayat C., Salem N., Chouery E., Corbani S., Moix I., Nicolas E., Morris M.A., de Moerloose P., Megarbane A.,
Haemophilia 14:709-716(2008)
A family with combined mutations of the hemophilia A and X-linked adrenoleukodystrophy genes.
Fogel B.L., Young P., Thompson A.R., Perlman S.,
Neurogenetics 9:215-218(2008)
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.
Cao W., Krishnaswamy S., Camire R.M., Lenting P.J., Zheng X.L.,
Proc Natl Acad Sci U S A 105:7416-7421(2008)
Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.
Meeks S.L., Healey J.F., Parker E.T., Barrow R.T., Lollar P.,
Blood 112:1151-1153(2008)
Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
Boekhorst J., Lari G.R., D'Oiron R., Costa J.M., Novakova I.R., Ala F.A., Lavergne J.M., VAN Heerde W.L.,
Haemophilia 14:729-735(2008)
Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII.
Nossent A.Y., Vos H.L., Rosendaal F.R., Bertina R.M., Eikenboom J.C.,
Haematologica 93:959-960(2008)
Simultaneous detection and epitope mapping of anti-factor VIII antibodies.
Lavigne-Lissalde G., Tarrade C., Lapalud P., Chtourou S., Schved J.F., Granier C., Villard-Saussine S.,
Thromb Haemost 99:1090-1096(2008)
Hemostatic and inflammatory risk factors for intracerebral hemorrhage in a pooled cohort.
Sturgeon J.D., Folsom A.R., Longstreth W.T. Jr., Shahar E., Rosamond W.D., Cushman M.,
Stroke 39:2268-2273(2008)
The role of VWF in the immunogenicity of FVIII.
Lacroix-Desmazes S., Repesse Y., Kaveri S.V., Dasgupta S.,
Thromb Res 122 Suppl 2:S3-6(2008)
Factor 8 (F8) gene mutation profile of Turkish hemophilia A patients with inhibitors.
Fidanci I.D., Kavakli K., Ucar C., Timur C., Meral A., Kilinc Y., Sayilan H., Kazanci E., Caglayan S.H.,
Blood Coagul Fibrinolysis 19:383-388(2008)
An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A.
Delumeau J.C., Ikegawa C., Yokoyama C., Haupt V.,
Thromb Haemost 100:32-37(2008)
Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.
Bowman K., Sarkar R., Raut S., Leong K.W.,
J Control Release 132:252-259(2008)
Molecular characteristics of the intron 22 homologs of the coagulation factor VIII gene: an update.
De Brasi C.D., Bowen D.J.,
J Thromb Haemost 6:1822-1824(2008)
Mass spectrometric kinetic analysis of human tyrosylprotein sulfotransferase-1 and -2.
Danan L.M., Yu Z., Hoffhines A.J., Moore K.L., Leary J.A.,
J Am Soc Mass Spectrom 19:1459-1466(2008)
Interaction of coagulation factor VIII with members of the low-density lipoprotein receptor family follows common mechanism and involves consensus residues within the A2 binding site 484-509.
Ananyeva N.M., Makogonenko Y.M., Sarafanov A.G., Pechik I.V., Gorlatova N., Radtke K.P., Shima M., Saenko E.L.,
Blood Coagul Fibrinolysis 19:543-555(2008)
Utility of an exon 14 BslI polymorphism for improved genetic diagnosis of hemophilia A in Indian population.
Mukundan P., Shetty S., Kulkarni B., Ghosh K.,
Prenat Diagn 28:920-922(2008)
High-resolution combined linkage physical map of short tandem repeat loci on human chromosome band Xq28 for indirect haemophilia A carrier detection.
Machado F.B., Medina-Acosta E.,
Haemophilia 15:297-308(2009)
Detection of large duplications within the factor VIII gene by MLPA.
Rost S., Loffler S., Pavlova A., Muller C.R., Oldenburg J.,
J Thromb Haemost 6:1996-1999(2008)
Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis.
Coulam C.B., Wallis D., Weinstein J., DasGupta D.S., Jeyendran R.S.,
Am J Reprod Immunol 60:426-431(2008)
Localization of human coagulation factor VIII (hFVIII) in transgenic rabbit by FISH-TSA: identification of transgene copy number and transmission to the next generation.
Krylov V., Tlapakova T., Macha J., Curlej J., Ryban L., Chrenek P.,
Folia Biol (Praha) 54:121-124(2008)
Structural basis of cargo membrane protein discrimination by the human COPII coat machinery.
Mancias J.D., Goldberg J.,
EMBO J. 27:2918-2928(2008)
The influence of von Willebrand factor on factor VIII activity measurements.
Butenas S., Parhami-Seren B., Mann K.G.,
J Thromb Haemost 7:132-137(2009)
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice.
ter Avest P.C., Fischer K., Mancuso M.E., Santagostino E., Yuste V.J., van den Berg H.M., van der Bom J.G., v Geet C.h., Peerlinck K., Rivard G., Chambost H., Auerswald G., Escuriola Ettinghausen C., Kreuz W., Santagostino E., Mancuso M.E., Gouw S.C., van den Berg H.M., Lee C.A.,
J Thromb Haemost 6:2048-2054(2008)
Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.
Fay P.J., Haidaris P.J., Smudzin T.M.,
J Biol Chem 266:8957-8962(1991)
[Frequency of intron 1 inversion of factor VIII gene in Chinese hemophilia A patients with case report of a female patient with heterozygous intron 1 inversion].
Yan Z.Y., Liang Y., Yan M., Fan L.K., Xiao B., Hua B.L., Liu J.Z., Zhao Y.Q.,
Zhonghua Yi Xue Za Zhi 88:2672-2674(2008)
Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study.
Bash L.D., Erlinger T.P., Coresh J., Marsh-Manzi J., Folsom A.R., Astor B.C.,
Am J Kidney Dis 53:596-605(2009)
Identification of plasmin-interactive sites in the light chain of factor VIII responsible for proteolytic cleavage at Lys36.
Nogami K., Nishiya K., Saenko E.L., Takeyama M., Ogiwara K., Yoshioka A., Shima M.,
J Biol Chem 284:6934-6945(2009)
Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
Damon A.L., Scudder L.E., Gnatenko D.V., Sitaraman V., Hearing P., Jesty J., Bahou W.F.,
Thromb Haemost 100:1111-1122(2008)
Screening for hemophilia A carriers: utility of PCR-RFLP--based polymorphism analysis.
Tasleem Raza S., Husain N., Kumar A.,
Clin Appl Thromb Hemost 15:78-83(2009)
Membrane fusion: grappling with SNARE and SM proteins.
Sudhof T.C., Rothman J.E.,
Science 323:474-477(2009)
A novel informative dinucleotide microsatellite marker located on human factor VIII intron 25.
Machado F.B., Duarte L.P., Medina-Acosta E.,
Haemophilia 15:613-614(2009)
Cleavage at Arg-1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII.
Newell J.L., Fay P.J.,
J Biol Chem 284:11080-11089(2009)
High levels of factor VIII and risk of extra-hepatic portal vein obstruction.
Martinelli I., Primignani M., Aghemo A., Reati R., Bucciarelli P., Fabris F., Battaglioli T., Dell'Era A., Mannucci P.M.,
J Hepatol 50:916-922(2009)
Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2).
Karatela R.A., Sainani G.S.,
Diabetes Res Clin Pract 84:e41-4(2009)
Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells.
van den Biggelaar M., Bouwens E.A., Kootstra N.A., Hebbel R.P., Voorberg J., Mertens K.,
Haematologica 94:670-678(2009)
Haemophilia A in two unrelated females due to F8 gene inversions combined with skewed inactivation of X chromosome.
Wang X., Lu Y., Ding Q., Dai J., Xi X., Wang H.,
Thromb Haemost 101:775-778(2009)
Inhibitors of factor VIII in black patients with hemophilia.
Viel K.R., Ameri A., Abshire T.C., Iyer R.V., Watts R.G., Lutcher C., Channell C., Cole S.A., Fernstrom K.M., Nakaya S., Kasper C.K., Thompson A.R., Almasy L., Howard T.E.,
N Engl J Med 360:1618-1627(2009)
The problem of novel FVIII missense mutations for haemophilia A genetic counseling.
Schneppenheim R., Schroder J., Obser T., Oyen F., Schneppenheim S., Oldenburg J.,
Hamostaseologie 29:158-160(2009)
Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S., Sharifian R.A., Khoshnoodi J., Karimi K., Milani M., Okita D.K., Shokri F., Conti-Fine B.M.,
Thromb Haemost 101:834-839(2009)
Factor VIII mutations in 42 Moldovan haemophilia A families, including 12 that are novel.
Sirocova N., Tsourea V., Vicol M., Barbacar N., Nakaya S.M., Thompson A.R., Pratt K.P.,
Haemophilia 15:942-951(2009)
Combined homology modelling and evolutionary significance evaluation of missense mutations in blood clotting factor VIII to highlight aspects of structure and function.
Markoff A., Gerke V., Bogdanova N.,
Haemophilia 15:932-941(2009)
Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.
Eckhardt C.L., Menke L.A., van Ommen C.H., van der Lee J.H., Geskus R.B., Kamphuisen P.W., Peters M., Fijnvandraat K.,
J Thromb Haemost 7:930-937(2009)
Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.
Ragni M.V., Ojeifo O., Feng J., Yan J., Hill K.A., Sommer S.S., Trucco M.N., Brambilla D.J., Brettler D., Forand P., Geary P., Ewenstein B., Sweeney C., Aledort L., Seremetis S., McCarthy J., DiMichele D., Goldberg I., Ingram R.,
Haemophilia 15:1074-1082(2009)
Factor IX Amagasaki: a new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activities.
Miyata T., Sakai T., Sugimoto M., Naka H., Yamamoto K., Yoshioka A., Fukui H., Mitsui K., Kamiya K., Umeyama H., Iwanaga S.,
Biochemistry 30:11286-11291(1991)
Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
Wootla B., Mahendra A., Dimitrov J.D., Friboulet A., Borel-Derlon A., Rao D.N., Uda T., Borg J.Y., Bayry J., Kaveri S.V., Lacroix-Desmazes S.,
FEBS Lett 583:2565-2572(2009)
Improved criterion-referenced assessment in indirect tracking of haemophilia A using a 0.23 cM-resolution dense polymorphic marker set.
Machado F.B., Duarte L.P., Medina-Acosta E.,
Haemophilia 15:1135-1142(2009)
Organisation of human ER-exit sites: requirements for the localisation of Sec16 to transitional ER.
Hughes H., Budnik A., Schmidt K., Palmer K.J., Mantell J., Noakes C., Johnson A., Carter D.A., Verkade P., Watson P., Stephens D.J.,
J. Cell Sci. 122:2924-2934(2009)
[Intron 1 and 22 inversions in factor VIII gene in patients with haemophilia A].
Li T., Dai J., Wu J.S., Ding Q.L., Ding K.Y., Zheng C.C., Sun P., Wang X.F.,
Zhonghua Xue Ye Xue Za Zhi 30:150-153(2009)
mTrs130 is a component of a mammalian TRAPPII complex, a Rab1 GEF that binds to COPI-coated vesicles.
Yamasaki A., Menon S., Yu S., Barrowman J., Meerloo T., Oorschot V., Klumperman J., Satoh A., Ferro-Novick S.,
Mol Biol Cell 20:4205-4215(2009)
Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity.
Meems H., Meijer A.B., Cullinan D.B., Mertens K., Gilbert G.E.,
Blood 114:3938-3946(2009)
Detection of new deletions in a group of Italian patients with Hemophilia A by multiplex ligation-dependent probe amplification.
Santacroce R., Longo V., Bafunno V., Sessa F., Chetta M., Sarno M., Bukvic N., D'Andrea G., Tomaiuolo M., Margaglione M.,
Genet Test Mol Biomarkers 13:573-576(2009)
Profiling of factor VIII mutations in Korean haemophilia A.
Hwang S.H., Kim M.J., Lim J.A., Kim H.C., Kim H.S.,
Haemophilia 15:1311-1317(2009)
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors.
Coppola A., Margaglione M., Santagostino E., Rocino A., Grandone E., Mannucci P.M., Di Minno G., Scaraggi F.A., Targhetta R., Veneto C., Tagariello G., Sartori R., Musso R., Musso M., Muleo G., Santoro R., Iannaccaro P., Biasoli C., Castaman G.,
J Thromb Haemost 7:1809-1815(2009)
Lack of association between FXIII-Val34Leu, FVII-323 del/ins, and transforming growth factor beta1 (915G/T) gene polymorphisms and bronchopulmonary dysplasia: a single-center study.
Atac F.B., Ince D.A., Verdi H., Gokmen Z., Yazici A.C., Gulcan H., Tarcan A., Taneri A., Sezgin E., Ozbek N.,
DNA Cell Biol 29:13-18(2010)
High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study.
Vormittag R., Simanek R., Ay C., Dunkler D., Quehenberger P., Marosi C., Zielinski C., Pabinger I.,
Arterioscler Thromb Vasc Biol 29:2176-2181(2009)
Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody.
Dimitrov J.D., Roumenina L.T., Andre S., Repesse Y., Atanasov B.P., Jacquemin M., Saint-Remy J.M., Bayry J., Kaveri S.V., Lacroix-Desmazes S.,
Mol Immunol 47:290-297(2009)
Study of mutations in Jordanian patients with haemophilia A: identification of five novel mutations.
Awidi A., Ramahi M., Alhattab D., Mefleh R., Dweiri M., Bsoul N., Magablah A., Arafat E., Barqawi M., Bishtawi M., Haddadeen E., Falah M., Tarawneh B., Swaidan S., Fauori S.,
Haemophilia 16:136-142(2010)
Is there any correlation between the elevated plasma levels and gene variations of factor VIII in Turkish thrombosis patients?
Ay M., Dolek B., Erdem G., Devecioglu O., Gozukirmizi N.,
Clin Appl Thromb Hemost 17:46-50(2011)
X-linked thrombophilia with a mutant factor IX (factor IX Padua).
Simioni P., Tormene D., Tognin G., Gavasso S., Bulato C., Iacobelli N.P., Finn J.D., Spiezia L., Radu C., Arruda V.R.,
N. Engl. J. Med. 361:1671-1675(2009)
Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.
Plantier J.L., Rolli V., Ducasse C., Dargaud Y., Enjolras N., Boukerche H., Negrier C.,
J Thromb Haemost 8:286-293(2010)
Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
BRIGHT Consortium, Talmud P.J., Drenos F., Shah S., Shah T., Palmen J., Verzilli C., Gaunt T.R., Pallas J., Lovering R., Li K., Casas J.P., Sofat R., Kumari M., Rodriguez S., Johnson T., Newhouse S.J., Dominiczak A., Samani N.J., Kjeldsen S.,
Am J Hum Genet 85:628-642(2009)
EF-hand domains of MCFD2 mediate interactions with both LMAN1 and coagulation factor V or VIII.
Zheng C., Liu H.H., Zhou J., Zhang B.,
Blood 115:1081-1087(2010)
A novel point mutation in severe haemophilia A: a further proof of genotype-phenotype correlation.
Borchiellini A., Bicocchi M.P., Aguzzi C., Valpreda A., Valeri F., Beggiato E., Acquila M., Schinco P.C.,
Haemophilia 16:554-555(2010)
Ten novel factor VIII (F8C) mutations in eighteen haemophilia A families detected in Singapore.
Abdul-Ghafar A., Bogdanova N., Lim L.C., Zhao Y., Markoff A., Tien S.L.,
Haemophilia 16:551-553(2010)
Interlocus non-random association of multiallelic polymorphisms spanning the coagulation factor VIII gene on human chromosome distalmost Xq28.
Medina-Acosta E.,
Haemophilia 16:525-537(2010)
Acquired haemophilia caused by non-haemophilic factor VIII gene variants.
Tiede A., Eisert R., Czwalinna A., Miesbach W., Scharrer I., Ganser A.,
Ann Hematol 89:607-612(2010)
Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
Takeyama M., Nogami K., Matsumoto T., Soeda T., Suzuki T., Hattori K., Shima M.,
Thromb Haemost 103:94-102(2010)
Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding.
Liu Z., Lin L., Yuan C., Nicolaes G.A., Chen L., Meehan E.J., Furie B., Furie B., Huang M.,
J Biol Chem 285:8824-8829(2010)
PHENIX: a comprehensive Python-based system for macromolecular structure solution.
Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H.,
Acta Crystallogr D Biol Crystallogr 66:213-221(2010)
Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII.
Passamonti S.M., Bucciarelli P., Bader R., Martinelli I.,
Thromb Res 126:243-245(2010)
Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.
Shovlin C.L., Angus G., Manning R.A., Okoli G.N., Govani F.S., Elderfield K., Birdsey G.M., Mollet I.G., Laffan M.A., Mauri F.A.,
PLoS One 5:e9154-e9154(2010)
Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.
Venkateswarlu D.,
BMC Struct Biol 10:7-7(2010)
Identification of seven novel mutations in the factor VIII gene in 18 unrelated Chinese patients with hemophilia A.
Hua B.L., Yan Z.Y., Liang Y., Yan M., Fan L.K., Li K.X., Xiao B., Liu J.Z., Zhao Y.Q.,
Chin Med J (Engl) 123:305-310(2010)
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.
Wellcome Trust Case Control Consortium, Smith N.L., Chen M.H., Dehghan A., Strachan D.P., Basu S., Soranzo N., Hayward C., Rudan I., Sabater-Lleal M., Bis J.C., de Maat M.P., Rumley A., Kong X., Yang Q., Williams F.M., Vitart V., Campbell H., Malarstig A., O'Donnell C.J.,
Circulation 121:1382-1392(2010)
Genetic analysis of haemophilia A in Taiwan.
Chen Y.C., Hu S.H., Cheng S.N., Chao T.Y.,
Haemophilia 16:538-544(2010)
New genetic associations detected in a host response study to hepatitis B vaccine.
Davila S., Froeling F.E., Tan A., Bonnard C., Boland G.J., Snippe H., Hibberd M.L., Seielstad M.,
Genes Immun 11:232-238(2010)
Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool.
Shahani T., Lavend'homme R., Luttun A., Saint-Remy J.M., Peerlinck K., Jacquemin M.,
Blood 115:4902-4909(2010)
The B-domain of Factor VIII reduces cell membrane attachment to host cells under serum free conditions.
Kolind M.P., Norby P.L., Flintegaard T.V., Berchtold M.W., Johnsen L.B.,
J Biotechnol 147:198-204(2010)
Coagulation procofactor activation by factor XIa.
Whelihan M.F., Orfeo T., Gissel M.T., Mann K.G.,
J Thromb Haemost 8:1532-1539(2010)
Identification of missense mutations in exon 16 of factor VIII gene in mild and moderate cases with hemophilia A.
Faridi N.J., Husain N., Siddiqi M.I., Kumar P., Bamezai R.N.,
Clin Appl Thromb Hemost 17:358-361(2011)
Factor VIII gene mutations profile in 148 Chinese hemophilia A subjects.
Xue F., Zhang L., Sui T., Ge J., Gu D., Du W., Zhao H., Yang R.,
Eur J Haematol 85:264-272(2010)
Protein sorting receptors in the early secretory pathway.
Dancourt J., Barlowe C.,
Annu Rev Biochem 79:777-802(2010)
A targeted siRNA screen to identify SNAREs required for constitutive secretion in mammalian cells.
Gordon D.E., Bond L.M., Sahlender D.A., Peden A.A.,
Traffic 11:1191-1204(2010)
Network organization of the human autophagy system.
Behrends C., Sowa M.E., Gygi S.P., Harper J.W.,
Nature 466:68-76(2010)
Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.
Mutch N.J., Koikkalainen J.S., Fraser S.R., Duthie K.M., Griffin M., Mitchell J., Watson H.G., Booth N.A.,
J Thromb Haemost 8:2017-2024(2010)
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction.
Hernandez-Romero D., Marin F., Lee K.W., Roldan V., Caturla J., Corral J., Valdes M., Lip G.Y., Vicente V., Gonzalez-Conejero R.,
Thromb Haemost 104:650-652(2010)
Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress.
Skipwith C.G., Cao W., Zheng X.L.,
J Biol Chem 285:28596-28603(2010)
Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.
Shi Q., Fahs S.A., Kuether E.L., Cooley B.C., Weiler H., Montgomery R.R.,
Blood 116:3049-3057(2010)
Factor XIII A subunit Val34Leu polymorphism in patients suffering atherothrombotic ischemic stroke.
Shemirani A.H., Pongracz E., Antalfi B., Adany R., Muszbek L.,
Thromb Res 126:159-162(2010)
Sources of variation in factor VIII, von Willebrand factor and fibrinogen measurements: implications for detecting deficiencies and increased plasma levels.
Bach J., Haubelt H., Hellstern P.,
Thromb Res 126:e188-95(2010)
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey S.D., Xie C., Do R., Montpetit A., Diaz R., Mohan V., Keavney B., Yusuf S., Gerstein H.C., Engert J.C., Anand S.,
Diabetes Care 33:2250-2253(2010)
Clinical and genetic findings in five female patients with haemophilia A: Identification of a novel missense mutation, p.Phe2127Ser.
Martin-Salces M., Vencesla A., Alvarez-Roman M.T., Rivas I., Fernandez I., Butta N., Baena M., Fuentes-Prior P., Tizzano E.F., Jimenez-Yuste V.,
Thromb Haemost 104:718-723(2010)
p125A exists as part of the mammalian Sec13/Sec31 COPII subcomplex to facilitate ER-Golgi transport.
Ong Y.S., Tang B.L., Loo L.S., Hong W.,
J Cell Biol 190:331-345(2010)
Polymorphisms and mutations in vWF and ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients with deep venous thrombosis.
Bittar L.F., de Paula E.V., Mello T.B., Siqueira L.H., Orsi F.L., Annichino-Bizzacchi J.M.,
Clin Appl Thromb Hemost 17:514-518(2011)
Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study.
Mulder R., van Schouwenburg I.M., Mahmoodi B.K., Veeger N.J., Mulder A.B., Middeldorp S., Kluin-Nelemans H.C., Lijfering W.M.,
Thromb Res 126:e249-54(2010)
Mechanisms of factor VIIa-catalyzed activation of factor VIII.
Soeda T., Nogami K., Matsumoto T., Ogiwara K., Shima M.,
J Thromb Haemost 8:2494-2503(2010)
Characterization of duplication breakpoints in the factor VIII gene.
Zimmermann M.A., Oldenburg J., Muller C.R., Rost S.,
J Thromb Haemost 8:2696-2704(2010)
Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation.
D'Amici G.M., Timperio A.M., Gevi F., Grazzini G., Zolla L.,
Electrophoresis 31:2730-2739(2010)
Molecular pathology of haemophilia A in Indian patients: identification of 11 novel mutations.
Nair P.S., Shetty S., Kulkarni B., Ghosh K.,
Clin Chim Acta 411:2004-2008(2010)
TRAPP complexes in membrane traffic: convergence through a common Rab.
Barrowman J., Bhandari D., Reinisch K., Ferro-Novick S.,
Nat Rev Mol Cell Biol 11:759-763(2010)
Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels.
Morange P.E., Saut N., Antoni G., Emmerich J., Tregouet D.A.,
J Thromb Haemost 9:229-231(2011)
Codon optimization of human factor VIII cDNAs leads to high-level expression.
Ward N.J., Buckley S.M., Waddington S.N., Vandendriessche T., Chuah M.K., Nathwani A.C., McIntosh J., Tuddenham E.G., Kinnon C., Thrasher A.J., McVey J.H.,
Blood 117:798-807(2011)
An integrative method for scoring candidate genes from association studies: application to warfarin dosing.
Tatonetti N.P., Dudley J.T., Sagreiya H., Butte A.J., Altman R.B.,
BMC Bioinformatics 11 Suppl 9:S9-S9(2010)
Binding of human factor VIII to phospholipid vesicles.
Gilbert G.E., Furie B.C., Furie B.,
J Biol Chem 265:815-822(1990)
Molecular analysis of FVIII gene in severe HA patients of Costa Rica.
Salazar-Sanchez L., Jimenez-Cruz G., Mendez M., Chaverri P., Alvarado P., Schroder W., Wulff K., Sandoval M., Herrmann F.H., Pavlova A., Oldenburg J.,
Hamostaseologie 30 Suppl 1:S150-2(2010)
Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype.
Oldenburg J., Pavlova A.,
Hamostaseologie 30:207-211(2010)
Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw S.C., Van Der Bom J.G., Van Den Berg H.M., Zewald R.A., Ploos Van Amstel J.K., Mauser-Bunschoten E.P.,
Haemophilia 17:275-281(2011)
High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients.
Gary T., Hafner F., Froehlich H., Stojakovic T., Scharnagl H., Pilger E., Brodmann M.,
Acta Haematol 124:214-217(2010)
Genotyping of intron 22-related rearrangements of F8 by inverse-shifting PCR in Egyptian hemophilia A patients.
Abou-Elew H., Ahmed H., Raslan H., Abdelwahab M., Hammoud R., Mokhtar D., Arnaout H.,
Ann Hematol 90:579-584(2011)
[Glycosylation modifications improve secretion and activity of intein spliced coagulation factor VIII].
ZHU F.X., LIU Z.L., MIAO J., QU H.G., CHI X.Y.,
Zhonghua Yi Xue Za Zhi 90:2570-2574(2010)
A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M., Holmstrom M., Wiman B.,
Thromb Res 127:47-50(2011)
Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
O'Brien D.P., Pattinson J.K., Tuddenham E.G.,
Blood 75:1664-1672(1990)
Kinetics of coagulation factor X activation by platelet-bound factor IXa.
Rawala-Sheikh R., Ahmad S.S., Ashby B., Walsh P.N.,
Biochemistry 29:2606-2611(1990)
Deletions and duplications in the factor VIII gene identified using multiplex ligation-dependent probe amplification.
Theophilus B.D., Baugh L.M., Guilliatt A.M., Motwani J., Williams M.D.,
J Thromb Haemost 9:605-607(2011)
A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function.
Lu J., Pipe S.W., Miao H., Jacquemin M., Gilbert G.E.,
Blood 117:3181-3189(2011)
Another step towards understanding hemophilia A molecular pathogenesis.
Goodeve A.C.,
J Thromb Haemost 8:2693-2695(2010)
Membrane-binding properties of the Factor VIII C2 domain.
Novakovic V.A., Cullinan D.B., Wakabayashi H., Fay P.J., Baleja J.D., Gilbert G.E.,
Biochem J 435:187-196(2011)
Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.
Summers R.J., Meeks S.L., Healey J.F., Brown H.C., Parker E.T., Kempton C.L., Doering C.B., Lollar P.,
Blood 117:3190-3198(2011)
Reversible activation of cellular factor XIII by calcium.
Kristiansen G.K., Andersen M.D.,
J Biol Chem 286:9833-9839(2011)
[Intragenic polymorphisms of factor VIII and IX genes and their utility in the indirect diagnosis of carriers of Haemophilias A and B].
Borjas L., Zabala W., Pineda L., Pardo T., Fernandez E., Zambrano M., Quintero J.M., Arteaga-Vizcaino M., Morales-Machin A., Delgado W.,
Invest Clin 51:391-401(2010)
The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.
Haghpanah S., Sahraiian M., Afrasiabi A., Enayati S., Peyvandi F., Karimi M.,
Haemophilia 17:820-821(2011)
[Mutation screening of the F VIII gene in 10 hemophilia A families].
LI W., HU X., GAO B.D., LI L.Y., LIAO Y., TANG X.M., TANG W.L., Lu G.X.,
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28:127-132(2011)
The role of P4-P3' residues flanking Arg336 in facilitating activated protein C-catalyzed cleavage and inactivation of factor VIIIa.
DeAngelis J.P., Varfaj F., Wakabayashi H., Fay P.J.,
Thromb Res 128:470-476(2011)
TFG-1 function in protein secretion and oncogenesis.
Witte K., Schuh A.L., Hegermann J., Sarkeshik A., Mayers J.R., Schwarze K., Yates J.R. III, Eimer S., Audhya A.,
Nat. Cell Biol. 13:550-558(2011)
High plasma level of factor VIII: an important risk factor for venous thromboembolism.
Ota S., Yamada N., Ogihara Y., Tsuji A., Ishikura K., Nakamura M., Wada H., Ito M.,
Circ J 75:1472-1475(2011)
Sequential interactions with Sec23 control the direction of vesicle traffic.
Lord C., Bhandari D., Menon S., Ghassemian M., Nycz D., Hay J., Ghosh P., Ferro-Novick S.,
Nature 473:181-186(2011)
Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B., Sack B.K., Nayak S., Markusic D.M., Mah C.S., Herzog R.W.,
J Thromb Haemost 9:1524-1533(2011)
Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
Ninivaggi M., Dargaud Y., van Oerle R., de Laat B., Hemker H.C., Lindhout T.,
J Thromb Haemost 9:1549-1555(2011)
Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response.
Brown H.C., Gangadharan B., Doering C.B.,
J Biol Chem 286:24451-24457(2011)
Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families--15 new mutations.
Silva Pinto C., Fidalgo T., Salvado R., Marques D., Goncalves E., Martinho P., Markoff A., Martins N., Leticia Ribeiro M.,
Haemophilia 18:129-138(2012)
Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.
Ogata K., Selvaraj S.R., Miao H.Z., Pipe S.W.,
J Thromb Haemost 9:1183-1190(2011)
Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction.
Griffiths A.E., Wang W., Hagen F.K., Fay P.J.,
J Thromb Haemost 9:1534-1540(2011)
Factor VIII haplotypes frequencies in Tunisian hemophiliacs A.
Elmahmoudi H., Belhedi N., Jlizi A., Zahra K., Meddeb B., Ben Ammar Elgaaied A., Gouider E.,
Diagn Pathol 6:54-54(2011)
Deep intronic variations may cause mild hemophilia A.
Castaman G., Giacomelli S.H., Mancuso M.E., D'Andrea G., Santacroce R., Sanna S., Santagostino E., Mannucci P.M., Goodeve A., Rodeghiero F.,
J Thromb Haemost 9:1541-1548(2011)
Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model.
van Helden P.M., Unterthurner S., Hermann C., Schuster M., Ahmad R.U., Schiviz A.N., Weiller M., Antoine G., Turecek P.L., Muchitsch E.M., Schwarz H.P., Reipert B.M.,
Blood 118:3698-3707(2011)
p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it.
Bowyer A.E., Goodeve A., Liesner R., Mumford A.D., Kitchen S., Makris M.,
Br J Haematol 154:618-625(2011)
Thrombomodulin-dependent effect of factor VLeiden mutation on factor XIII activation.
Koncz Z., Bagoly Z., Haramura G., Mezei Z.A., Muszbek L.,
Thromb Res 129:508-513(2012)
Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels.
Antoni G., Oudot-Mellakh T., Dimitromanolakis A., Germain M., Cohen W., Wells P., Lathrop M., Gagnon F., Morange P.E., Tregouet D.A.,
BMC Med Genet 12:102-102(2011)
Persistent high factor VIII activity leading to increased thrombin generation - a prospective cohort study.
Ryland J.K., Lawrie A.S., Mackie I.J., Machin S.J.,
Thromb Res 129:447-452(2012)
Storage of factor VIII variants with impaired von Willebrand factor binding in Weibel-Palade bodies in endothelial cells.
van den Biggelaar M., Bouwens E.A., Voorberg J., Mertens K.,
PLoS One 6:e24163-e24163(2011)
Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.
Hollestelle M.J., Lai K.W., van Deuren M., Lenting P.J., de Groot P.G., Sprong T., Bovenschen N.,
PLoS One 6:e24216-e24216(2011)
Factor VIII alters tubular organization and functional properties of von Willebrand factor stored in Weibel-Palade bodies.
Bouwens E.A., Mourik M.J., van den Biggelaar M., Eikenboom J.C., Voorberg J., Valentijn K.M., Mertens K.,
Blood 118:5947-5956(2011)
Interactions between residues 2228-2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation.
Soeda T., Nogami K., Ogiwara K., Shima M.,
Thromb Haemost 106:893-900(2011)
Downregulation of CD40 signal and induction of TGF-beta by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII.
Gaitonde P., Peng A., Straubinger R.M., Bankert R.B., Balu-Iyer S.V.,
J Pharm Sci 101:48-55(2012)
Toward an understanding of the protein interaction network of the human liver.
Wang J., Huo K., Ma L., Tang L., Li D., Huang X., Yuan Y., Li C., Wang W., Guan W., Chen H., Jin C., Wei J., Zhang W., Yang Y., Liu Q., Zhou Y., Zhang C., Yang X.,
Mol Syst Biol 7:536-536(2011)
The acute phase reaction explains only a part of initially elevated factor VIII:C levels: a prospective cohort study in patients with venous thrombosis.
Tichelaar V., Mulder A., Kluin-Nelemans H., Meijer K.,
Thromb Res 129:183-186(2012)
COPII and COPI traffic at the ER-Golgi interface.
Szul T., Sztul E.,
Physiology (Bethesda) 26:348-364(2011)
Interpretation of correlations between coagulation factors FV, FVIII and vWF in normal and type 2 diabetes mellitus patients.
Dayer M.R., Mard-Soltani M., Dayer M.S., Alavi S.M.,
Pak J Biol Sci 14:552-557(2011)
Elevated plasma factor VIII levels in patients with venous thrombosis--constitutional risk factor or secondary epiphenomenon?
Ryan K., O'Donnell J.S.,
Thromb Res 129:105-106(2012)
[Does FVIII-activity increase with age in patients with haemophilia A and carriers of haemophilia A?].
Delbruck C., Haferland I., Scholz K., Asmelash G., Makki V., Muller S., Krekeler S., Alesci S., Miesbach W.,
Hamostaseologie 31 Suppl 1:S24-8(2011)
Development of inhibitors in haemophilia. Ongoing epidemiological study.
Serban M., Mihailov D., Pop L., Ionita H., Ursu E., Talpos-Niculescu S., Ritli L., Baghiu D., Uscatescu V., Petrovanu C., Stancu P., Savescu D., Cucuianu A., Schramm W.,
Hamostaseologie 31 Suppl 1:S20-3(2011)
Unusual genomic rearrangements in introns 1 and 22 of the F8 gene.
Zimmermann M.A., Oldenburg J., Muller C.R., Rost S.,
Hamostaseologie 31 Suppl 1:S69-73(2011)
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
Miller C.H., Benson J., Ellingsen D., Driggers J., Payne A., Kelly F.M., Soucie J.M., Craig Hooper W., Abshire T.C., Dunn A.L., Kempton C.L., Bockenstedt P.L., Brettler D.B., Di Paola J.A., Radhi M., Lentz S.R., Massey G., Barrett J.C., Creary M.,
Haemophilia 18:375-382(2012)
Identification of 123 previously unreported mutations in the F8 gene of Iranian patients with haemophilia A.
Ravanbod S., Rassoulzadegan M., Rastegar-Lari G., Jazebi M., Enayat S., Ala F.,
Haemophilia 18:e340-6(2012)
Identification and characterization of mutations in the promoter region of the factor VIII gene.
Zimmermann M.A., Meier D., Oldenburg J., Muller C.R., Rost S.,
J Thromb Haemost 10:314-317(2012)
Sec24p and Sec16p cooperate to regulate the GTP cycle of the COPII coat.
Kung L.F., Pagant S., Futai E., D'Arcangelo J.G., Buchanan R., Dittmar J.C., Reid R.J., Rothstein R., Hamamoto S., Snapp E.L., Schekman R., Miller E.A.,
EMBO J 31:1014-1027(2012)
Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis.
Tuinenburg A., Rutten A., Kavousi M., Leebeek F.W., Ypma P.F., Laros-van Gorkom B.A., Nijziel M.R., Kamphuisen P.W., Mauser-Bunschoten E.P., Roosendaal G., Biesma D.H., van der Lugt A., Hofman A., Witteman J.C., Bots M.L., Schutgens R.E.,
Arterioscler Thromb Vasc Biol 32:799-804(2012)
Factor VIII:C levels in pregnancies complicated by pre-eclampsia and intrauterine growth restriction.
Haumonte J.B., Camoin-Jau L., Banet J., Mazouni C., Heckenroth H., Dignat-George F., Bretelle F.,
Int J Gynaecol Obstet 116:258-259(2012)
Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.
Campos M., Buchanan A., Yu F., Barbalic M., Xiao Y., Chambless L.E., Wu K.K., Folsom A.R., Boerwinkle E., Dong J.F.,
Blood 119:1929-1934(2012)
Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase.
Takeyama M., Wakabayashi H., Fay P.J.,
Biochemistry 51:820-828(2012)
Functional mapping of the A2 domain from human factor VIII.
Plantier J.L., Saboulard D., Pellequer J.L., Negrier C., Delcourt M.,
Thromb Haemost 107:315-327(2012)
Screening of intron 1 inversion and three intragenic factor VIII gene polymorphisms in Pakistani hemophilia A families.
Bugvi S.M., Imran M., Mahmood S., Hafeez R., Fatima W., Sohail S.,
Blood Coagul Fibrinolysis 23:132-137(2012)
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.
Gouw S.C., van den Berg H.M., Oldenburg J., Astermark J., de Groot P.G., Margaglione M., Thompson A.R., van Heerde W., Boekhorst J., Miller C.H., le Cessie S., van der Bom J.G.,
Blood 119:2922-2934(2012)
Identification of an ancient haemophilia A splice site mutation.
Reitter-Pfoertner S., von Haeseler A., Horvath B., Sunder-Plassmann R., Tiedje V., Pabinger I., Mannhalter C.,
Thromb Res 130:445-450(2012)
The thrombophilic pattern of different clinical manifestations of venous thromboembolism: a survey of 443 cases of venous thromboembolism.
Grifoni E., Marcucci R., Ciuti G., Cenci C., Poli D., Mannini L., Liotta A.A., Miniati M., Abbate R., Prisco D.,
Semin Thromb Hemost 38:230-234(2012)
Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis.
Rios D.R., Fernandes A.P., Figueiredo R.C., Guimaraes D.A., Ferreira C.N., Simoes E Silva A.C., Carvalho M.G., Gomes K.B., Dusse L.M.,
J Thromb Thrombolysis 33:416-421(2012)
Heme binds to factor VIII and inhibits its interaction with activated factor IX.
Repesse Y., Dimitrov J.D., Peyron I., Farrokhi Moshai E., Kiger L., Dasgupta S., Delignat S., Marden M.C., Kaveri S.V., Lacroix-Desmazes S.,
J Thromb Haemost 10:1062-1071(2012)
Towards automated crystallographic structure refinement with phenix.refine.
Afonine P.V., Grosse-Kunstleve R.W., Echols N., Headd J.J., Moriarty N.W., Mustyakimov M., Terwilliger T.C., Urzhumtsev A., Zwart P.H., Adams P.D.,
Acta Crystallogr D Biol Crystallogr 68:352-367(2012)
Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.
Dimitrov J.D., Christophe O.D., Kang J., Repesse Y., Delignat S., Kaveri S.V., Lacroix-Desmazes S.,
Biochemistry 51:4108-4116(2012)
Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.
Gilbert G.E., Novakovic V.A., Kaufman R.J., Miao H., Pipe S.W.,
Blood 120:1923-1932(2012)
F8 gene dosage defects in atypical patients with severe haemophilia A.
Vencesla A., Baena M., Garrido R.P., Nunez R., Velasco F., Rosell J., Villar A., Jimenez-Yuste V., Baiget M., Tizzano E.F.,
Haemophilia 18:708-713(2012)
Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack B.K., Merchant S., Markusic D.M., Nathwani A.C., Davidoff A.M., Byrne B.J., Herzog R.W.,
PLoS One 7:e37671-e37671(2012)
Insights into structural and regulatory roles of Sec16 in COPII vesicle formation at ER exit sites.
Yorimitsu T., Sato K.,
Mol Biol Cell 23:2930-2942(2012)
Identification and characterization of an adenine to guanine transition within intron 10 of the factor VIII gene as a causative mutation in a patient with mild haemophilia A.
Inaba H., Koyama T., Shinozawa K., Amano K., Fukutake K.,
Haemophilia 19:100-105(2013)
Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
Cao W., Sabatino D.E., Altynova E., Lange A.M., Casina V.C., Camire R.M., Zheng X.L.,
J Biol Chem 287:32459-32466(2012)
First report of molecular diagnosis of Tunisian hemophiliacs A: identification of 8 novel causative mutations.
Elmahmoudi H., Khodjet-el-khil H., Wigren E., Jlizi A., Zahra K., Pellechia D., Vinciguerra C., Meddeb B., Elggaaied A.B., Gouider E.,
Diagn Pathol 7:93-93(2012)
A possible mechanism for Inv22-related F8 large deletions in severe hemophilia A patients with high responding factor VIII inhibitors.
Fujita J., Miyawaki Y., Suzuki A., Maki A., Okuyama E., Murata M., Takagi A., Murate T., Suzuki N., Matsushita T., Saito H., Kojima T.,
J Thromb Haemost 10:2099-2107(2012)
Spectrum of F8 gene mutations in haemophilia A patients from Slovenia.
Debeljak M., Kitanovski L., Trampus Bakija A., Benedik Dolnicar M.,
Haemophilia 18:e420-3(2012)
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
Schwarz J., Astermark J., Menius E.D., Carrington M., Donfield S.M., Gomperts E.D., Nelson G.W., Oldenburg J., Pavlova A., Shapiro A.D., Winkler C.A., Berntorp E., Liesner R., Windyga J., Klukowska A., Kavakli K., Santagostino E., Mancuso M.E., Micic D.,
Haemophilia 19:113-118(2013)
Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme.
Bajaj S.P., Spitzer S.G., Welsh W.J., Warn-Cramer B.J., Kasper C.K., Birktoft J.J.,
J Biol Chem 265:2956-2961(1990)
Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.
Kannicht C., Ramstrom M., Kohla G., Tiemeyer M., Casademunt E., Walter O., Sandberg H.,
Thromb Res 131:78-88(2013)
Analysis of F8 mRNA in haemophilia A patients with silent mutations or presumptive splice site mutations.
Zimmermann M.A., Gehrig A., Oldenburg J., Muller C.R., Rost S.,
Haemophilia 19:310-317(2013)
A strategy for the molecular diagnosis in hemophilia a in Chinese population.
He Z., Chen J., Xu S., Chen S., Xiao X., Li H., Guo Y., Jiang W.,
Cell Biochem Biophys 65:463-472(2013)
Aberrant F8 gene intron 1 inversion with concomitant duplication and deletion in a severe hemophilia A patient from Southern Italy.
Sanna V., Ceglia C., Tarsitano M., Lombardo B., Coppola A., Zarrilli F., Castaldo G., Di Minno G.,
J Thromb Haemost 11:195-197(2013)
Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.
Castro-Nunez L., Bloem E., Boon-Spijker M.G., van der Zwaan C., van den Biggelaar M., Mertens K., Meijer A.B.,
J Biol Chem 288:393-400(2013)
In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.
Golder M., Mewburn J., Lillicrap D.,
Thromb Haemost 109:53-60(2013)
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
Peters R.T., Toby G., Lu Q., Liu T., Kulman J.D., Low S.C., Bitonti A.J., Pierce G.F.,
J Thromb Haemost 11:132-141(2013)
Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.
Takeyama M., Wakabayashi H., Fay P.J.,
Thromb Haemost 109:187-198(2013)
Prothrombotic polymorphisms in patients with Raynaud's phenomenon and migraine.
Takats A.T., Shemirani A.H., Zsori K.S., Andras C., Csiki Z.,
Acta Physiol Hung 99:430-435(2012)
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
Whelan S.F., Hofbauer C.J., Horling F.M., Allacher P., Wolfsegger M.J., Oldenburg J., Male C., Windyga J., Tiede A., Schwarz H.P., Scheiflinger F., Reipert B.M.,
Blood 121:1039-1048(2013)
Intron 22 homologous regions are implicated in exons 1-22 duplications of the F8 gene.
Lannoy N., Grisart B., Eeckhoudt S., Verellen-Dumoulin C., Lambert C., Vikkula M., Hermans C.,
Eur J Hum Genet 21:970-976(2013)
Significance of F8 missense mutations with respect to inhibitor formation.
Schwaab R., Pavlova A., Albert T., Caspers M., Oldenburg J.,
Thromb Haemost 109:464-470(2013)
Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A.
Stoof S.C., Sanders Y.V., Petrij F., Cnossen M.H., de Maat M.P., Leebeek F.W., Kruip M.J.,
Thromb Haemost 109:440-449(2013)
Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
Knappe S., Gorczyca M.E., Jilma B., Derhaschnig U., Hartmann R., Palige M., Scheiflinger F., Dockal M.,
Thromb Haemost 109:450-457(2013)
The diversity of the immune response to the A2 domain of human factor VIII.
Markovitz R.C., Healey J.F., Parker E.T., Meeks S.L., Lollar P.,
Blood 121:2785-2795(2013)
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
Eikenboom J., Federici A.B., Dirven R.J., Castaman G., Rodeghiero F., Budde U., Schneppenheim R., Batlle J., Canciani M.T., Goudemand J., Peake I., Goodeve A., Peake I., Goodeve A., Rodeghiero F., Castaman G., Tosetto A., Federici A.B., Hill F.,
Blood 121:2336-2339(2013)
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner J.I., Iacobelli N.P., Sabatino D.E., Ivanciu L., Zhou S., Poncz M., Camire R.M., Arruda V.R.,
Blood 121:4396-4403(2013)
The highly conserved COPII coat complex sorts cargo from the endoplasmic reticulum and targets it to the golgi.
Lord C., Ferro-Novick S., Miller E.A.,
Cold Spring Harb Perspect Biol 5:0-0(2013)
Copy number variations of the F8 gene are associated with venous thromboembolism.
Shen W., Gu Y., Zhu R., Zhang L., Zhang J., Ying C.,
Blood Cells Mol Dis 50:259-262(2013)
Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.
Walter J.D., Werther R.A., Polozova M.S., Pohlman J., Healey J.F., Meeks S.L., Lollar P., Spiegel P.C. Jr.,
J Biol Chem 288:9905-9914(2013)
Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties.
Svensson L.A., Thim L., Olsen O.H., Nicolaisen E.M.,
Biol Chem 394:761-765(2013)
Inhibition of TFG function causes hereditary axon degeneration by impairing endoplasmic reticulum structure.
Beetz C., Johnson A., Schuh A.L., Thakur S., Varga R.E., Fothergill T., Hertel N., Bomba-Warczak E., Thiele H., Nurnberg G., Altmuller J., Saxena R., Chapman E.R., Dent E.W., Nurnberg P., Audhya A.,
Proc. Natl. Acad. Sci. U.S.A. 110:5091-5096(2013)
Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa.
Takeyama M., Wintermute J.M., Manithody C., Rezaie A.R., Fay P.J.,
Biochemistry 52:2228-2235(2013)
Crystal structure of human tyrosylprotein sulfotransferase-2 reveals the mechanism of protein tyrosine sulfation reaction.
Teramoto T., Fujikawa Y., Kawaguchi Y., Kurogi K., Soejima M., Adachi R., Nakanishi Y., Mishiro-Sato E., Liu M.C., Sakakibara Y., Suiko M., Kimura M., Kakuta Y.,
Nat. Commun. 4:1572-1572(2013)
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.
Carcao M.D., van den Berg H.M., Ljung R., Mancuso M.E., Altisent C., Auerswald G., Chalmers E., Chambost H., Cid A., Claeyssens S., Clausen N., Fischer K., Peerlinck K., Kobelt R., Kreuz W., Escuriola C., Kurnik K., Liesner R., Rivard G.,
Blood 121:3946-3952(2013)
Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors.
Zhu F., Liu Z., Wang X., Miao J., Qu H., Chi X.,
Sci China Life Sci 56:262-267(2013)
Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: a comprehensive Argentine study of inhibitor risks.
Rossetti L.C., Szurkalo I., Radic C.P., Abelleyro M.M., Primiani L., Neme D., Candela M., Bianco R.P., de Tezanos Pinto M., Larripa I.B., De Brasi C.D.,
Haemophilia 19:511-518(2013)
Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry.
Pandey G.S., Tseng S.C., Howard T.E., Sauna Z.E.,
Biomed Res Int 2013:793502-793502(2013)
Factor VIIIa A2 subunit shows a high affinity interaction with factor IXa: contribution of A2 subunit residues 707-714 to the interaction with factor IXa.
Griffiths A.E., Rydkin I., Fay P.J.,
J Biol Chem 288:15057-15064(2013)
Domain organization of membrane-bound factor VIII.
Stoilova-McPhie S., Lynch G.C., Ludtke S., Pettitt B.M.,
Biopolymers 99:448-459(2013)
Compromised shear-dependent cleavage of type 2N von Willebrand factor variants by ADAMTS13 in the presence of factor VIII.
Skipwith C.G., Haberichter S.L., Gehrand A., Zheng X.L.,
Thromb Haemost 110:202-204(2013)
Coagulation potential of immobilised factor VIII in flow-dependent fibrin generation on platelet surfaces.
Doi M., Sugimoto M., Matsui H., Matsunari Y., Shima M.,
Thromb Haemost 110:316-322(2013)
High precision platelet releasate definition by quantitative reversed protein profiling--brief report.
Wijten P., van Holten T., Woo L.L., Bleijerveld O.B., Roest M., Heck A.J., Scholten A.,
Arterioscler Thromb Vasc Biol 33:1635-1638(2013)
Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A.
Chen J., Chung D.W., Le J., Ling M., Konkle B.A., Lopez J.A.,
J Thromb Haemost 11:1769-1772(2013)
Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project.
Johnsen J.M., Auer P.L., Morrison A.C., Jiao S., Wei P., Haessler J., Fox K., McGee S.R., Smith J.D., Carlson C.S., Smith N., Boerwinkle E., Kooperberg C., Nickerson D.A., Rich S.S., Green D., Peters U., Cushman M., Jackson R.,
Blood 122:590-597(2013)
Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.
Pandey G.S., Yanover C., Howard T.E., Sauna Z.E.,
PLoS Comput Biol 9:e1003066-e1003066(2013)
Organization of the ER-Golgi interface for membrane traffic control.
Brandizzi F., Barlowe C.,
Nat Rev Mol Cell Biol 14:382-392(2013)
Structural characterization of carbohydrate binding by LMAN1 protein provides new insight into the endoplasmic reticulum export of factors V (FV) and VIII (FVIII).
Zheng C., Page R.C., Das V., Nix J.C., Wigren E., Misra S., Zhang B.,
J Biol Chem 288:20499-20509(2013)
Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.
Kurasawa J.H., Shestopal S.A., Karnaukhova E., Struble E.B., Lee T.K., Sarafanov A.G.,
J Biol Chem 288:22033-22041(2013)
Deep intronic 'mutations' cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA.
Pezeshkpoor B., Zimmer N., Marquardt N., Nanda I., Haaf T., Budde U., Oldenburg J., El-Maarri O.,
J Thromb Haemost 11:1679-1687(2013)
Combined deficiency of coagulation factors V and VIII: an update.
Zheng C., Zhang B.,
Semin Thromb Hemost 39:613-620(2013)
A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.
Bloem E., Meems H., van den Biggelaar M., Mertens K., Meijer A.B.,
J Biol Chem 288:26105-26111(2013)
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
Eckhardt C.L., van Velzen A.S., Peters M., Astermark J., Brons P.P., Castaman G., Cnossen M.H., Dors N., Escuriola-Ettingshausen C., Hamulyak K., Hart D.P., Hay C.R., Haya S., van Heerde W.L., Hermans C., Holmstrom M., Jimenez-Yuste V., Keenan R.D., Fijnvandraat K.,
Blood 122:1954-1962(2013)
Factor VIII mutations and inhibitor formation in a southern Brazilian population.
Rosset C., Gorziza R.P., Botton M.R., Salzano F.M., Bandinelli E.,
Blood Coagul Fibrinolysis 25:125-127(2014)
Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.
Bloem E., van den Biggelaar M., Wroblewska A., Voorberg J., Faber J.H., Kjalke M., Stennicke H.R., Mertens K., Meijer A.B.,
J Biol Chem 288:29670-29679(2013)
Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
Wakabayashi H., Fay P.J.,
J Biol Chem 288:31289-31297(2013)
Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.
Walter J.D., Werther R.A., Brison C.M., Cragerud R.K., Healey J.F., Meeks S.L., Lollar P., Spiegel P.C. Jr.,
Blood 122:4270-4278(2013)
Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein.
Pahl S., Pavlova A., Driesen J., Oldenburg J.,
Thromb Haemost 111:58-66(2014)
In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
Pashov A.D., Calvez T., Gilardin L., Maillere B., Repesse Y., Oldenburg J., Pavlova A., Kaveri S.V., Lacroix-Desmazes S.,
Haemophilia 20:176-184(2014)
Tethering the assembly of SNARE complexes.
Hong W., Lev S.,
Trends Cell Biol 24:35-43(2014)
Production of factor VIII by human liver sinusoidal endothelial cells transplanted in immunodeficient uPA mice.
Fomin M.E., Zhou Y., Beyer A.I., Publicover J., Baron J.L., Muench M.O.,
PLoS One 8:e77255-e77255(2013)
Selection and characterisation of FVIII-specific single chain variable fragments.
Naumann A., Scherger A.K., Neuwirth J., Orlowski A., Kahle J., Schwabe D., Konigs C.,
Hamostaseologie 33 Suppl 1:S39-45(2013)
Methylation analysis of the promoter region and intron 1 of the factor VIII gene in haemophilia A patients.
Zimmermann M.A., Hansmann T., Haaf T., Oldenburg J., Muller C.R., Rost S.,
Hamostaseologie 33 Suppl 1:S46-9(2013)
Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function.
Ocak G., Vossen C.Y., Lijfering W.M., Verduijn M., Dekker F.W., Rosendaal F.R., Cannegieter S.C.,
Circulation 129:683-691(2014)
First molecular analysis of F8 gene in algeria: identification of two novel mutations.
Abdi M., Zemani-Fodil F., Fodil M., Aberkane M.S., Touhami H., Saidi-Mehtar N., Costa C., Boudjema A.,
Clin Appl Thromb Hemost 20:741-748(2014)
Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Dockal M., Hartmann R., Fries M., Thomassen M.C., Heinzmann A., Ehrlich H., Rosing J., Osterkamp F., Polakowski T., Reineke U., Griessner A., Brandstetter H., Scheiflinger F.,
J Biol Chem 289:1732-1741(2014)
F8 genetic analysis strategies when standard approaches fail.
Pezeshkpoor B., Pavlova A., Oldenburg J., El-Maarri O.,
Hamostaseologie 34:167-173(2014)
Compound heterozygous hemophilia A in a female patient and the identification of a novel missense mutation, p.Met1093Ile.
Qiao S.K., Ren H.Y., Ren J.H., Guo X.N.,
Mol Med Rep 9:466-470(2014)
Changes in procoagulants track longitudinally with insulin resistance: findings from the coronary artery risk development in young adults (CARDIA) study.
Klein O.L., Okwuosa T., Chan C., Schreiner P., Kanaya A.M., Liu K., Green D.,
Diabet Med 31:462-465(2014)
Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results.
Hsu P., Zantek N.D., Meijer P., Hayward C.P., Brody J., Zhang X., Smock K.J., Van Cott E.M.,
Semin Thromb Hemost 40:232-238(2014)
Intragenic integration in DLC1 sustains factor VIII expression in primary human cells without insertional oncogenicity.
Sivalingam J., Phan T.T., Kon O.L.,
Gene Ther 21:402-412(2014)
Plasma factor VIII in non-puerperal cerebral venous thrombosis: a prospective case-control study.
Anadure R.K., Nagaraja D., Christopher R.,
J Neurol Sci 339:140-143(2014)
Heckathorn disease revisited.
Nand S., Barton K., Schultz R., Klein M., Kini A.,
Blood 123:1429-1431(2014)
Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa.
Wakabayashi H., Wintermute J.M., Fay P.J.,
Thromb Haemost 112:43-52(2014)
Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation.
Zimmermann M.A., Oldenburg J., Muller C.R., Rost S.,
Haemophilia 20:e215-21(2014)
Higher frequency of CD4(+)CD25(high) Treg cells in hemophilia patients with factor VIII inhibitor.
Ding K.Y., Ji W.C., Wu J.S., Li T., Sheng Y.Y.,
Genet Mol Res 13:1774-1781(2014)
Solution structure of the major factor VIII binding region on von Willebrand factor.
Shiltagh N., Kirkpatrick J., Cabrita L.D., McKinnon T.A., Thalassinos K., Tuddenham E.G., Hansen D.F.,
Blood 123:4143-4151(2014)
Acute cerebral infarct with elevated factor VIII level during the thrombocytopenic stage after hematopoietic stem cell transplant.
Hsiao H.H., Huang H.L., Wang H.C., Tsai Y.F., Liu T.C., Chang C.S., Lin S.F.,
Exp Clin Transplant 12:171-172(2014)
Changes in the Factor VIII C2 domain upon membrane binding determined by hydrogen-deuterium exchange MS.
Pantazatos D., Gessner C.R., Woods V.L. Jr., Gilbert G.E.,
Biochem J 461:443-451(2014)
Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.
Pinto P., Ghosh K., Shetty S.,
Blood Cells Mol Dis 53:161-163(2014)
Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.
Nair P.S., Shetty S.D., Chandrakala S., Ghosh K.,
PLoS One 9:e97337-e97337(2014)
In sickness and in health: the role of TRAPP and associated proteins in disease.
Brunet S., Sacher M.,
Traffic 15:803-818(2014)
Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs.
Park C.Y., Kim J., Kweon J., Son J.S., Lee J.S., Yoo J.E., Cho S.R., Kim J.H., Kim J.S., Kim D.W.,
Proc Natl Acad Sci U S A 111:9253-9258(2014)
Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.
Kosloski M.P., Shetty K.A., Wakabayashi H., Fay P.J., Balu-Iyer S.V.,
AAPS J 16:1038-1045(2014)
In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma.
Pieters J., Lindhout T., Hemker H.C.,
Blood 74:1021-1024(1989)
Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.
Hill-Eubanks D.C., Parker C.G., Lollar P.,
Proc Natl Acad Sci U S A 86:6508-6512(1989)
Von Willebrand Factor and Factor VIII levels in Egyptian children with newly diagnosed acute lymphoblastic leukemia in relation to peripheral blast cells and steroid therapy.
El Sherif N.H., Narouz M.F., Elkerdany T.A., El Habashy S.A.,
J Pediatr Hematol Oncol 36:518-523(2014)
Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study.
Venkateswarlu D.,
Biochem Biophys Res Commun 452:408-414(2014)
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.
Chen T.C., Lin K.T., Chen C.H., Lee S.A., Lee P.Y., Liu Y.W., Kuo Y.L., Wang F.S., Lai J.M., Huang C.Y.,
J Proteome Res 13:5339-5346(2014)
Mercury metallation of the copper protein azurin and structural insight into possible heavy metal reactivity.
Zampino A.P., Masters F.M., Bladholm E.L., Panzner M.J., Berry S.M., Leeper T.C., Ziegler C.J.,
J Inorg Biochem 141:152-160(2014)
Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas P.M., Vanijcharoenkarn K., Markovitz R.C., Meeks S.L., Doering C.B.,
J Thromb Haemost 13:72-81(2015)
Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
Boylan B., Rice A.S., Dunn A.L., Tarantino M.D., Brettler D.B., Barrett J.C., Miller C.H., Abshire T.C., Kempton C.L., Bockenstedt P.L., Di Paola J.A., Radhi M., Lentz S.R., Massey G., Neff A.T., Shapiro A.D., Wicklund B.M., Manco-Johnson M.J., Yaish H.,
J Thromb Haemost 13:47-53(2015)
Molecular simulation studies of human coagulation factor VIII C domain-mediated membrane binding.
Du J., Wichapong K., Hackeng K.M., Nicolaes G.A.,
Thromb Haemost 113:373-384(2015)
Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.
Ivaskevicius V., Goldmann G., Horneff S., Marquardt N., Klein C., Albert T., Zeitler H., Oldenburg J.,
Hamostaseologie 34 Suppl 1:S9-12(2014)
The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.
Sauna Z.E., Lozier J.N., Kasper C.K., Yanover C., Nichols T., Howard T.E.,
Blood 125:223-228(2015)
p115-SNARE interactions: a dynamic cycle of p115 binding monomeric SNARE motifs and releasing assembled bundles.
Wang T., Grabski R., Sztul E., Hay J.C.,
Traffic 16:148-171(2015)
Characterisation and quantification of F8 transcripts of ten putative splice site mutations.
Liang Q., Xiang M., Lu Y., Ruan Y., Ding Q., Wang X., Xi X., Wang H.,
Thromb Haemost 113:585-592(2015)
Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites.
Kahle J., Orlowski A., Stichel D., Becker-Peters K., Kabiri A., Healey J.F., Brettschneider K., Naumann A., Scherger A.K., Lollar P., Schwabe D., Konigs C.,
Thromb Haemost 113:396-405(2015)
Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis.
Bittar L.F., Mazetto B.d.e. M., Orsi F.L., Collela M.P., De Paula E.V., Annichino-Bizzacchi J.M.,
Thromb Res 135:497-501(2015)
TFG clusters COPII-coated transport carriers and promotes early secretory pathway organization.
Johnson A., Bhattacharya N., Hanna M., Pennington J.G., Schuh A.L., Wang L., Otegui M.S., Stagg S.M., Audhya A.,
EMBO J 34:811-827(2015)
Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M., Kovac Z., Tomasevic Z., Vucicevic S., Djordjevic V., Pruner I., Radojkovic D.,
Eur J Intern Med 26:63-67(2015)
Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
Lapalud P., Rothschild C., Mathieu-Dupas E., Balicchi J., Gruel Y., Laune D., Molina F., Schved J.F., Granier C., Lavigne-Lissalde G.,
J Thromb Haemost 13:540-547(2015)
Interaction between VWF and FVIII in treating VWD.
Miesbach W., Berntorp E.,
Eur J Haematol 95:449-454(2015)
Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation.
Radic C.P., Rossetti L.C., Abelleyro M.M., Tetzlaff T., Candela M., Neme D., Sciuccati G., Bonduel M., Medina-Acosta E., Larripa I.B., de Tezanos Pinto M., De Brasi C.D.,
J Thromb Haemost 13:530-539(2015)
Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.
Gunasekera D., Ettinger R.A., Nakaya Fletcher S., James E.A., Liu M., Barrett J.C., Withycombe J., Matthews D.C., Epstein M.S., Hughes R.J., Pratt K.P.,
Blood 126:895-904(2015)
SEC16 in COPII coat dynamics at ER exit sites.
Sprangers J., Rabouille C.,
Biochem Soc Trans 43:97-103(2015)
Molecular characterization of ten F8 splicing mutations in RNA isolated from patient's leucocytes: assessment of in silico prediction tools accuracy.
Martorell L., Corrales I., Ramirez L., Parra R., Raya A., Barquinero J., Vidal F.,
Haemophilia 21:249-257(2015)
Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism.
Kooiman J., den Exter P.L., Kilicsoy I., Cannegieter S.C., Eikenboom J., Huisman M.V., Klok F.A., Versteeg H.H.,
J Thromb Thrombolysis 40:323-330(2015)
Factoring in Factor VIII With Acute Ischemic Stroke.
Siegler J.E., Samai A., Albright K.C., Boehme A.K., Martin-Schild S.,
Clin Appl Thromb Hemost 21:597-602(2015)
Gene-centric approach identifies new and known loci for FVIII activity and VWF antigen levels in European Americans and African Americans.
Tang W., Cushman M., Green D., Rich S.S., Lange L.A., Yang Q., Tracy R.P., Tofler G.H., Basu S., Wilson J.G., Keating B.J., Weng L.C., Taylor H.A., Jacobs D.R. Jr., Delaney J.A., Palmer C.D., Young T., Pankow J.S., Folsom A.R.,
Am J Hematol 90:534-540(2015)
Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B., Rice A.S., De Staercke C., Eyster M.E., Yaish H.M., Knoll C.M., Bean C.J., Miller C.H., Abshire T.C., Dunn A., Kempton C.L., Bockenstedt P.L., Brettler D.B., Di Paola J.A., Radhi M., Lentz S.R., Massey G., Barrett J.C., Leissinger C.,
J Thromb Haemost 13:1036-1042(2015)
Overrepresentation of missense mutations in mild hemophilia A patients from Belgium: founder effect or independent occurrence?
Lannoy N., Lambert C., Vikkula M., Hermans C.,
Thromb Res 135:1057-1063(2015)
In silico analyses of missense mutations in coagulation factor VIII: identification of severity determinants of haemophilia A.
Sengupta M., Sarkar D., Ganguly K., Sengupta D., Bhaskar S., Ray K.,
Haemophilia 21:662-669(2015)
Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.
van den Biggelaar M., Madsen J.J., Faber J.H., Zuurveld M.G., van der Zwaan C., Olsen O.H., Stennicke H.R., Mertens K., Meijer A.B.,
J Biol Chem 290:16463-16476(2015)
Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene.
Bach J.E., Wolf B., Oldenburg J., Muller C.R., Rost S.,
Thromb Haemost 114:757-767(2015)
Deep sequencing reveals different compositions of mRNA transcribed from the F8 gene in a panel of FVIII-producing CHO cell lines.
Kaas C.S., Bolt G., Hansen J.J., Andersen M.R., Kristensen C.,
Biotechnol J 10:1081-1089(2015)
Ca(2+) concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy.
Bonazza K., Rottensteiner H., Schrenk G., Fiedler C., Scheiflinger F., Allmaier G., Turecek P.L., Friedbacher G.,
Anal Bioanal Chem 407:6051-6056(2015)
Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
Lu Q., Yang L., Manithody C., Wang X., Rezaie A.R.,
Biochemistry 54:3814-3821(2015)
Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).
Trampus Bakija A., Debeljak M., Preloznik Zupan I., Benedik Dolnicar M., Kovac J., Jazbec J.,
Blood Transfus 13:622-630(2015)
Mini-gene assays confirm the splicing effect of deep intronic variants in the factor VIII gene.
Bach J.E., Muller C.R., Rost S.,
Thromb Haemost 115:222-224(2016)
Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study.
Yap E.S., Timp J.F., Flinterman L.E., van Hylckama Vlieg A., Rosendaal F.R., Cannegieter S.C., Lijfering W.M.,
J Thromb Haemost 13:1833-1842(2015)
Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study.
Timp J.F., Lijfering W.M., Flinterman L.E., van Hylckama Vlieg A., le Cessie S., Rosendaal F.R., Cannegieter S.C.,
J Thromb Haemost 13:1823-1832(2015)
Application of indirect linkage analysis and direct genotyping to hemophilia A carrier detection in Sichuan, China.
Sun P., Ma L., Diao G., Li C.Q., Lin F.Z.,
Genet Mol Res 14:8229-8235(2015)
Membrane Interaction of the Factor VIIIa Discoidin Domains in Atomistic Detail.
Madsen J.J., Ohkubo Y.Z., Peters G.H., Faber J.H., Tajkhorshid E., Olsen O.H.,
Biochemistry 54:6123-6131(2015)
Complexity and diversity of F8 genetic variations in the 1000 genomes.
Li J.N., Carrero I.G., Dong J.F., Yu F.L.,
J Thromb Haemost 13:2031-2040(2015)
Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.
Baumgartner C.K., Zhang G., Kuether E.L., Weiler H., Shi Q., Montgomery R.R.,
J Thromb Haemost 13:2210-2219(2015)
Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings.
Turner N.A., Moake J.L.,
PLoS One 10:e0140740-e0140740(2015)
F8 intron 22 inversions and SNP rs73563631 in unrelated families with severe haemophilia A: clinical features and gene testing implications.
Abelleyro M.M., Rossetti L.C., Curto M.d.e. L., Radic C.P., Marchione V.D., De Brasi C.D.,
Thromb Haemost 115:678-681(2016)
Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients.
Esnault S., Kelly E.A., Sorkness R.L., Evans M.D., Busse W.W., Jarjour N.N.,
J Allergy Clin Immunol 137:767-73.e6(2016)
Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody.
Wuerth M.E., Cragerud R.K., Spiegel P.C.,
Sci Rep 5:17216-17216(2015)
Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial.
Mansouritorghabeh H., Shirdel A.,
J Thromb Haemost 14:336-339(2016)
Five int22h homologous copies at the Xq28 locus identified in intron22 inversion type 3 of the Factor VIII gene.
Lannoy N., Ravoet M., Grisart B., Fretigny M., Vikkula M., Hermans C.,
Thromb Res 137:224-227(2016)
In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs.
Wu Y., Hu Z., Li Z., Pang J., Feng M., Hu X., Wang X., Lin-Peng S., Liu B., Chen F., Wu L., Liang D.,
Sci Rep 6:18865-18865(2016)
F8 gene mutation profile in Indian hemophilia A patients: Identification of 23 novel mutations and factor VIII inhibitor risk association.
Pinto P., Ghosh K., Shetty S.,
Mutat Res 786:27-33(2016)
Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.
Jourdy Y., Nougier C., Roualdes O., Fretigny M., Durand B., Negrier C., Vinciguerra C.,
Haemophilia 22:583-589(2016)
Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.
O'Sullivan J.M., Jenkins P.V., Rawley O., Gegenbauer K., Chion A., Lavin M., Byrne B., O'Kennedy R., Preston R.J., Brophy T.M., O'Donnell J.S.,
Arterioscler Thromb Vasc Biol 36:855-863(2016)
Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo.
Pan J., Dinh T.T., Rajaraman A., Lee M., Scholz A., Czupalla C.J., Kiefel H., Zhu L., Xia L., Morser J., Jiang H., Santambrogio L., Butcher E.C.,
Blood 128:104-109(2016)
Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.
Lyu C., Xue F., Liu X., Liu W., Fu R., Sun T., Wu R., Zhang L., Li H., Zhang D., Yang R., Zhang L.,
Haemophilia 22:e427-34(2016)
[Detection and genetic counseling of F8 gene inversions for patients with severe hemophilia A].
Bai N., Wu Q., Liu N., Chen D., Zhao Z., Kong X.,
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 33:508-510(2016)
Association between the Val34Leu polymorphism in blood coagulation factor XIII-A and intracerebral hemorrhage: a meta-analysis.
Ye X., Ye B.,
Genet Mol Res 15:0-0(2016)
Association of Single Nucleotide Polymorphisms in the ST3GAL4 Gene with VWF Antigen and Factor VIII Activity.
Song J., Xue C., Preisser J.S., Cramer D.W., Houck K.L., Liu G., Folsom A.R., Couper D., Yu F., Dong J.F.,
PLoS One 11:e0160757-e0160757(2016)
Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
Pipe S.W., Montgomery R.R., Pratt K.P., Lenting P.J., Lillicrap D.,
Blood 128:2007-2016(2016)
Combined variants in factor VIII and prostaglandin synthase-1 amplify hemorrhage severity across three generations of descendants.
Nance D., Campbell R.A., Rowley J.W., Downie J.M., Jorde L.B., Kahr W.H., Mereby S.A., Tolley N.D., Zimmerman G.A., Weyrich A.S., Rondina M.T.,
J Thromb Haemost 14:2230-2240(2016)
Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes.
Bastida J.M., Gonzalez-Porras J.R., Jimenez C., Benito R., Ordonez G.R., Alvarez-Roman M.T., Fontecha M.E., Janusz K., Castillo D., Fisac R.M., Garcia-Frade L.J., Aguilar C., Martinez M.P., Bermejo N., Herrero S., Balanzategui A., Martin-Antoran J.M., Ramos R., Sarasquete M.E.,
Thromb Haemost 117:66-74(2017)
The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.
Gangadharan B., Ing M., Delignat S., Peyron I., Teyssandier M., Kaveri S.V., Lacroix-Desmazes S.,
Haematologica 102:271-281(2017)
Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE.
Young P.A., Migliorini M., Strickland D.K.,
J Biol Chem 291:26035-26044(2016)
Mutational spectrum and deep intronic variants in the factor VIII gene of haemophilia A patients. Identification by next generation sequencing.
Bach J.E., Oldenburg J., Muller C.R., Rost S.,
Hamostaseologie 36:S25-S28(2016)
Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania.
Ivaskevicius V., Pezeshkpoor B., Biswas A., Goldmann G., Horneff S., Gimbutyte M., Malciute L., Jurgutis R., Oldenburg J.,
Hamostaseologie 36:S29-S33(2016)
[Genetic analysis for a family affected with hemophilia type A due to a large deletion of F8 gene].
Bai N., Mei S., Liu N., Zhao Z., Meng J., Kong X.,
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 33:782-785(2016)
Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
Greig J.A., Wang Q., Reicherter A.L., Chen S.J., Hanlon A.L., Tipper C.H., Clark K.R., Wadsworth S., Wang L., Wilson J.M.,
Hum Gene Ther 28:392-402(2017)
Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking.
Ebberink E.H., Bouwens E.A., Bloem E., Boon-Spijker M., van den Biggelaar M., Voorberg J., Meijer A.B., Mertens K.,
Haematologica 102:686-694(2017)
Von Willebrand factor processing.
Brehm M.A.,
Hamostaseologie 37:59-72(2017)
Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
Wei W., Zheng C., Zhu M., Zhu X., Yang R., Misra S., Zhang B.,
Sci Rep 7:45033-45033(2017)
The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
Leksa N.C., Chiu P.L., Bou-Assaf G.M., Quan C., Liu Z., Goodman A.B., Chambers M.G., Tsutakawa S.E., Hammel M., Peters R.T., Walz T., Kulman J.D.,
J Thromb Haemost 15:1167-1179(2017)
A common polymorphism decreases LRP1 mRNA stability and is associated with increased plasma factor VIII levels.
Lee J.D., Hsiao K.M., Chang P.J., Chen C.C., Kuo Y.W., Huang Y.C., Hsu H.L., Lin Y.H., Wu C.Y., Huang Y.C., Lee M., Hsu C.Y., Pan Y.T., Kuo C.Y., Lin C.H.,
Biochim Biophys Acta Mol Basis Dis 1863:1690-1698(2017)
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
Lai J., Hough C., Tarrant J., Lillicrap D.,
Blood 129:3147-3154(2017)
Relevance of ethnic differences in factor XIII activity on laboratory reference ranges.
Wong W.H., Tan C.K., Ho L.P., Tan C.W., Kaur H., Lee L.H., Ng H.J.,
Int J Lab Hematol 39:e113-e116(2017)
Complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis.
Chen C., Xie X., Wu X., Lu Y., Wang X., Wu W., Hu Y., Ding Q.,
Thromb Haemost 117:1478-1485(2017)
CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro.
Vollack N., Friese J., Bergmann S., Tiede A., Werwitzke S.,
Thromb Haemost 117:1679-1687(2017)
Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
Kahle J., Orlowski A., Stichel D., Healey J.F., Parker E.T., Jacquemin M., Krause M., Tiede A., Schwabe D., Lollar P., Konigs C.,
Blood 130:808-816(2017)
Cellular uptake of coagulation factor VIII: Elusive role of the membrane-binding spikes in the C1 domain.
Castro-Nunez L., Koornneef J.M., Rondaij M.G., Bloem E., van der Zwaan C., Mertens K., Meijer A.B., Meems H.,
Int J Biochem Cell Biol 89:34-41(2017)
An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII.
Pezeshkpoor B., Schreck U., Biswas A., Driesen J., Berkemeier A.C., Pavlova A., Muller J., Oldenburg J.,
PLoS One 12:e0180456-e0180456(2017)
Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
Kamikubo Y., Mendolicchio G.L., Zampolli A., Marchese P., Rothmeier A.S., Orje J.N., Gale A.J., Krishnaswamy S., Gruber A., Ostergaard H., Petersen L.C., Ruf W., Ruggeri Z.M.,
Blood 130:1661-1670(2017)
[Genetic and prenatal diagnosis for a haemophilia A family with two novel mutations of F8 gene].
Li T., Hou Q., Liu H., Xiao H., Zhang B., Liu S., Yang Y., Zhang C., Ding X., Liao S.,
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 34:486-489(2017)
Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y., Luo X., Schroeder J.A., Chen J., Baumgartner C.K., Hu J., Shi Q.,
J Thromb Haemost 15:1994-2004(2017)
Factor XIII Subunit A in the Skin: Applications in Diagnosis and Treatment.
Paragh L., Torocsik D.,
Biomed Res Int 2017:3571861-3571861(2017)
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.
Donadon I., McVey J.H., Garagiola I., Branchini A., Mortarino M., Peyvandi F., Bernardi F., Pinotti M.,
Haematologica 103:344-350(2018)
Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization.
Jourdy Y., Janin A., Fretigny M., Lienhart A., Negrier C., Bozon D., Vinciguerra C.,
Am J Hum Genet 102:199-206(2018)
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
Spena S., Garagiola I., Cannavo A., Mortarino M., Mannucci P.M., Rosendaal F.R., Peyvandi F., El-Beshlawy A., Elalfy M., Ramanan V., Eshghi P., Hanagavadi S., Varadarajan R., Karimi M., Manglani M.V., Ross C., Young G., Seth T., Zulfikar B.,
J Thromb Haemost 16:778-790(2018)
Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.
Wei W., Misra S., Cannon M.V., Yang R., Zhu X., Gilmore R., Zhu M., Zhang B.,
Biochem J 475:873-886(2018)
Somatic/Germinal Mosaicism of a F8 Promoter Deletion Confounds Clinical Predictions in a Family with Haemophilia A: Key Role of Genotype Quantitation.
Abelleyro M.M., Marchione V.D., Elhelou L., Radic C.P., Rossetti L.C., Neme D., De Brasi C.D.,
Thromb Haemost 118:617-620(2018)
F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review.
Luna-Zaizar H., Gonzalez-Alcazar J.A., Evangelista-Castro N., Aguilar-Lopez L.B., Ruiz-Quezada S.L., Beltran-Miranda C.P., Jaloma-Cruz A.R.,
Blood Cells Mol Dis 71:45-52(2018)
Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis.
Sinegre T., Duron C., Lecompte T., Pereira B., Massoulier S., Lamblin G., Abergel A., Lebreton A.,
J Thromb Haemost 16:1132-1140(2018)
Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
Takeyama M., Nogami K., Sasai K., Furukawa S., Shima M.,
Thromb Haemost 118:830-841(2018)
Recurrent F8 and F9 gene variants result from a founder effect in two large French haemophilia cohorts.
Lassalle F., Marmontel O., Zawadzki C., Fretigny M., Bouvagnet P., Vinciguerra C.,
Haemophilia 24:e213-e221(2018)
Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS).
Zakai N.A., Judd S.E., Kissela B., Howard G., Safford M.M., Cushman M.,
Thromb Haemost 118:1305-1315(2018)
Detection of F8 mutations in carriers and patients with severe hemophilia A. Identification of a novel mutation.
Lopez-Vasquez L., Albanez S., Pestana C., Porco A.,
Invest Clin 57:377-387(2016)
The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.
Przeradzka M.A., Meems H., van der Zwaan C., Ebberink E.H.T.M., van den Biggelaar M., Mertens K., Meijer A.B.,
Biochem J 475:2819-2830(2018)
The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.
Dong X., Leksa N.C., Chhabra E.S., Arndt J.W., Lu Q., Knockenhauer K.E., Peters R.T., Springer T.A.,
Blood 133:1523-1533(2019)
Case Report: Development of Factor VIII Inhibitor in a Patient with an Uncommon de novo Mutation in the Factor VIII Gene.
Wyatt K.D., Coon L.M., Rusk D.N., Rodriguez V., Warad D.M.,
Acta Haematol 141:129-134(2019)
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.
Eaton D., Rodriguez H., Vehar G.A.,
Biochemistry 25:505-512(1986)
Single-molecule measurement and bioinformatics analysis suggest a preferred orientation of human coagulation factor VIII on hydrophobic interfaces.
Cheng J., Geng F., Hu J., Lu J.,
Biophys Chem 248:9-15(2019)
In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
Pezeshkpoor B., Gazorpak M., Berkemeier A.C., Singer H., Pavlova A., Biswas A., Oldenburg J.,
Ann Hematol 98:1855-1865(2019)
Single-molecule nanomechanical spectroscopy shows calcium ions contribute to chain association and structural flexibility of blood clotting factor VIII.
Cheng J., Wang Y., Pan Y., Li X., Hu J., Lu J.,
Biochem Biophys Res Commun 513:857-861(2019)
Deep intronic variant c.5999-277G>A of F8 gene may be a hot spot mutation for mild hemophilia A patients without mutation in exonic DNA.
Chang C.Y., Perng C.L., Cheng S.N., Hu S.H., Wu T.Y., Lin S.Y., Chen Y.C.,
Eur J Haematol 103:47-55(2019)
Recurrent and novel disease-causing F8 variants in boys with severe haemophilia A in Poland.
Janczar S., Babol-Pokora K., Jatczak-Pawlik I., Wypyszczak K., Klukowska A., Laguna P., Kostrzewska M., Wegner O., Zielinski J., Koltan A., Bobrowska H., Woznica-Karczmarz I., Dakowicz L., Wlazlowski M., Ruranska I., Dobaczewski G., Radwanska M., Karolczyk G., Mlynarski W.,
Haemophilia 25:e311-e314(2019)
Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.
Kaufman R.J., Wasley L.C., Dorner A.J.,
J Biol Chem 263:6352-6362(1988)
Association of the factor VIII light chain with von Willebrand factor.
Lollar P., Hill-Eubanks D.C., Parker C.G.,
J Biol Chem 263:10451-10455(1988)
The 3.2 A structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.
Smith I.W., d'Aquino A.E., Coyle C.W., Fedanov A., Parker E.T., Denning G., Spencer H.T., Lollar P., Doering C.B., Spiegel P.C. Jr.,
J Thromb Haemost 18:57-69(2020)
Physiological Roles of the von Willebrand Factor-Factor VIII Interaction.
Kiouptsi K., Reinhardt C.,
Subcell Biochem 94:437-464(2020)
Different Clinical Phenotypes Caused by Three F8 Missense Mutations in Three Chinese Families with Moderate Hemophilia A.
Huang L., Li L., Li Q., Chen J., Lin S., Li K., Fan D., Jin W., Li Y., Yang X., Xiong Y., Li M., Yang X.,
DNA Cell Biol 39:1685-1690(2020)
Amino acid sequence of human von Willebrand factor.
Titani K., Kumar S., Takio K., Ericsson L.H., Wade R.D., Ashida K., Walsh K.A., Chopek M.W., Sadler J.E., Fujikawa K.,
Biochemistry 25:3171-3184(1986)
Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.
Usharani P., Warn-Cramer B.J., Kasper C.K., Bajaj S.P.,
J Clin Invest 75:76-83(1985)
Structure of human factor VIII.
Vehar G.A., Keyt B., Eaton D., Rodriguez H., O'Brien D.P., Rotblat F., Oppermann H., Keck R., Wood W.I., Harkins R.N., Tuddenham E.G., Lawn R.M., Capon D.J.,
Nature 312:337-342(1984)
Characterization of the proteins of isolated human platelet alpha-granules. Evidence for a separate alpha-granule-pool of the glycoproteins IIb and IIIa.
Gogstad G.O., Hagen I., Korsmo R., Solum N.O.,
Biochim Biophys Acta 670:150-162(1981)
Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region.
Hoeben R.C., Fallaux F.J., Cramer S.J., van den Wollenberg D.J., van Ormondt H., Briet E., van der Eb A.J.,
Blood 85:2447-2454(1995)
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
Vlot A.J., Koppelman S.J., van den Berg M.H., Bouma B.N., Sixma J.J.,
Blood 85:3150-3157(1995)
Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling.
Miyata T., Kuze K., Matsusue T., Komooka H., Kamiya K., Umeyama H., Matsui A., Kato H., Yoshioka A.,
Br J Haematol 88:156-165(1994)
A comparison of the allelic frequencies of ten DNA polymorphisms associated with factor VIII and factor IX genes in Thai and Western European populations.
Goodeve A.C., Chuansumrit A., Sasanakul W., Isarangkura P., Preston F.E., Peake I.R.,
Blood Coagul Fibrinolysis 5:29-35(1994)
Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage.
Michnick D.A., Pittman D.D., Wise R.J., Kaufman R.J.,
J Biol Chem 269:20095-20102(1994)
Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
Johnson D.J., Pemberton S., Acquila M., Mori P.G., Tuddenham E.G., O'Brien D.P.,
Thromb Haemost 71:428-433(1994)
Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562.
Regan L.M., Lamphear B.J., Huggins C.F., Walker F.J., Fay P.J.,
J Biol Chem 269:9445-9452(1994)
Platelet alpha-granules.
Harrison P., Cramer E.M.,
Blood Rev 7:52-62(1993)
Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine.
Gilbert G.E., Arena A.A.,
J Biol Chem 271:11120-11125(1996)
Mammalian Sly1 regulates syntaxin 5 function in endoplasmic reticulum to Golgi transport.
Dascher C., Balch W.E.,
J. Biol. Chem. 271:15866-15869(1996)
Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
Pipe S.W., Kaufman R.J.,
J Biol Chem 271:25671-25676(1996)
Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.
Voorberg J., de Laaf R.T., Koster P.M., van Mourik J.A.,
Biochem J 318:931-937(1996)
Protein interactions regulating vesicle transport between the endoplasmic reticulum and Golgi apparatus in mammalian cells.
Hay J.C., Chao D.S., Kuo C.S., Scheller R.H.,
Cell 89:149-158(1997)
The vesicle docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated manner.
Nakamura N., Lowe M., Levine T.P., Rabouille C., Warren G.,
Cell 89:445-455(1997)
An isoform of the Golgi t-SNARE, syntaxin 5, with an endoplasmic reticulum retrieval signal.
Hui N., Nakamura N., Sonnichsen B., Shima D.T., Nilsson T., Warren G.,
Mol. Biol. Cell 8:1777-1787(1997)
The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.
Amano K., Sarkar R., Pemberton S., Kemball-Cook G., Kazazian H.H. Jr., Kaufman R.J.,
Blood 91:538-548(1998)
Association of a common polymorphism in the factor XIII gene with myocardial infarction.
Kohler H.P., Stickland M.H., Ossei-Gerning N., Carter A., Mikkola H., Grant P.J.,
Thromb Haemost 79:8-13(1998)
Tyrosylprotein sulfotransferase: purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins.
Ouyang Y.-B., Lane W.S., Moore K.L.,
Proc. Natl. Acad. Sci. U.S.A. 95:2896-2901(1998)
Structure and topography of the membrane-binding C2 domain of factor VIII in the presence of dodecylphosphocholine micelles.
Veeraraghavan S., Baleja J.D., Gilbert G.E.,
Biochem J 332:549-555(1998)
Biosynthesis, assembly and secretion of coagulation factor VIII.
Kaufman R.J., Pipe S.W., Tagliavacca L., Swaroop M., Moussalli M.,
Blood Coagul Fibrinolysis 8 Suppl 2:S3-14(1997)
Localization, dynamics, and protein interactions reveal distinct roles for ER and Golgi SNAREs.
Hay J.C., Klumperman J., Oorschot V., Steegmaier M., Kuo C.S., Scheller R.H.,
J. Cell Biol. 141:1489-1502(1998)
Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.
Saenko E.L., Scandella D., Yakhyaev A.V., Greco N.J.,
J Biol Chem 273:27918-27926(1998)
The life cycle of coagulation factor VIII in view of its structure and function.
Lenting P.J., van Mourik J.A., Mertens K.,
Blood 92:3983-3996(1998)
Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
Pipe S.W., Eickhorst A.N., McKinley S.H., Saenko E.L., Kaufman R.J.,
Blood 93:176-183(1999)
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Catto A.J., Kohler H.P., Coore J., Mansfield M.W., Stickland M.H., Grant P.J.,
Blood 93:906-908(1999)